Archive for September, 2022

In March 2011, a chance meeting between two women changed history without anyone being aware of it. It happened in a cafe in San Juan, Puerto Rico, when the American molecular biologist Jennifer Doudna was introduced to Emmanuelle Charpentier, a French professor of Armenian origin in the same field. They hit it off and, within hours, agreed to a research collaboration. The result, a year later, was the discovery of the CRISPR system: a technology that can be used to edit genes.

Eleven years later, CRISPR is a ubiquitous tool in any molecular biology laboratory in the world, allowing research to be carried out at a speed and cost that were previously unimaginable. Gene editing has also made its way into the experimental treatment of many diseases. CRISPR makes mind-blowing applications possible, such as taking white blood cells from a person, rewriting their genomes to transform them into cancer-killing machines and reinjecting them to fight tumors that havent responded to conventional treatments.

Charpentier and Doudna won the 2020 Nobel Prize in Chemistry for discovering CRISPR. Charpentier, 53, made her fundamental contribution while searching for a way to kill an implacable enemy: the streptococcus pyogenes bacteria, one of the top 10 causes of deadly infections on the planet. It is known as the flesh-eating bacteria because of the horrible wounds it causes if it gets under the skin and reaches the muscle a type of injury that has been documented since the 5th century, appearing in terrible situations. For instance, it inflicted combatants in the US Civil War and heroin addicts in 1990s San Francisco. This bacteria has even become immune to conventional antibiotics.

The investigation into the molecular mechanisms that this bacterium uses to survive external threats was key to discovering CRISPR. The microbes acted as a kind of bacterial immune system, capable of remembering precise fragments of the virus genome, to then cut the virus DNA. But the genome of a virus has millions of letters arranged one after the other how did these microbes manage to identify the genome of the virus and cut it in the exact place?

A few months before the historic meeting in Puerto Rico, Charpentiers team had discovered an RNA molecule that was essential to guiding a pair of molecular scissors to the exact sequence of the genome of each virus. This was key to putting together all the elements needed to build the new CRISPR gene-editing tool.

Three months ago, CRISPR Therapeutics the company Charpentier founded in 2019 published preliminary results from a clinical trial showing that 15 patients with beta thalassemia a severe type of anemia that requires lifelong reliance on blood transfusions had gone months without needing them after receiving a drug that edited the gene that caused the disease.

In early September, Charpentier traveled to Yerevan, Armenia to be one of the main speakers at the Starmus VI Festival. In her interview with EL PAS, the scientist explains that she is still focused on the same goal as she was years ago: looking for new forms of gene editing to combat antibiotic-resistant infections. These superbugs already kill more people than AIDS, malaria and some cancers. For her, one of the greatest dangers we face is that the basic sciences which require years of hard work are no longer attractive to young people, who will need to invent new treatments and medicines in the future. This interview has been edited for the purposes of clarity and brevity.

Question. Where did your interest in science come from?

Answer. At the age of 15, I was obsessed with monasteries I wanted to be a nun for a while. Thats maybe reflected in my work as a scientist: many hours are spent alone, cut off from the world. This is what I did at the University of Ume, in Sweden. I made the key discovery for CRISPR there, while living in my scientific monastery in northern Sweden. At the same time, I was very interested in detective stories, searching for enigmas.

Q. Do you believe in God?

A. My parents were Catholics, but they belonged to a very modern and up-to-date branch of Catholicism, with working-class priests. I grew up in this environment and practiced, but I havent done it for a long time. For me, believing in God is believing in the good of the human being, the best version of humanity.

Q. Are microbes superior to humans?

A. Probably, yes. Long after we have disappeared from the planet, they will still be here. And lets not forget that they already existed long before we appeared! They have solved key problems in their own way. They know how to communicate, adapt, fight theyre extremely versatile. And were talking about a huge community, with millions of different species and an exciting social life.

Q. Social life?

A. They are very social. We can learn a lot from them. The human body contains more bacterial cells than human cells. And this community partly determines how we react to stimuli, why we get sick, how our metabolism works, even some brain functions. I believe that the challenge for human beings is to adapt to the enormous change that is taking place in the microbial universe. We have seen it with a single microbe: SARS-CoV-2. And we are going to see it with new viruses that are yet to come. Many of them will, in part, be driven by human activities on the planet.

Q. Just four years ago, when you spoke to EL PAS, there were hardly any applications of CRISPR in health. Now, especially after the pandemic, there are more and more. Whats the next big step?

A. In origin, CRISPR is an immune system that allows bacteria to defend themselves against viruses. In the coming years, we must perfect the system and be able to use it in a more personalized way. Its the future the study of microbes can solve some of the biggest problems facing humanity. We can create crops that are more resistant to changes in climate and the environment. But the next big step as is usually the case in science will be totally unexpected.

Q. And what role will CRISPR play in treating disease?

A. This tool could help interfere with human metabolism in a beneficial way, to eliminate the negative effects of common diets in the Western world. These same problems are becoming more and more prevalent in Asia [the developing world], because the populations metabolism is not prepared for this type of diet, with lots of meat and enriched carbohydrates. One of the key ailments in this field would be diabetes, for example. Also obesity and infectious diseases.

Q. You head the Max Planck Institute for the Science of Pathogens (Berlin). One of its goals is to combat antibiotic-resistant infections, which are expected to cause the next pandemic.

A. My lab doesnt have many people. We continue to work in a humble way on the specific mechanisms existing in bacteria, so we can identify therapeutic targets and have new antibiotics ready to combat future infections. The development of antibiotics has stagnated in the last 20 years because the pharmaceutical industry is not interested in developing them. We are now starting to see small biotech companies tackling this challenge. I think it is very important to focus on this.

Q. Dont we already know how resistant bacteria are able to make us sick?

A. There are many different mechanisms. The problem is that, as soon as you create a new antibiotic, the bacteria develop immunity to it. Its important to continue researching in this field, looking for new ways to intervene and have different therapeutic compounds. A vaccine is one thing, but you also need antivirals. You have to have different strategies.

Q. What other future issues are you worried about?

A. Being well-armed against resistant bacteria requires a lot of work, a lot of research time. The efforts of many people in different fields, from biologists to doctors, entrepreneurs and businessmen. But the most indispensable are the basic scientists. With the noise of the world we live in today, we see many scientists who finish their doctorates and abandon research. Young generations cant find their place in the academic world, which has not evolved in 30 years. Meanwhile, everything is moving faster and faster, including business. In the US, you can create a biotech company almost instantly and be successful very quickly.

The basic sciences which rely on public funding are ceasing to be attractive, both in terms of funding and mentality. Young people do not want to wait so many years to see the fruits of their labor. Science is being flooded with politics. The system of scientific publications has been filled with marketing. If it continues like this, it will be a very serious problem. Scientists also teach at universities: they are the teachers of the next generations. Without them, not one, but several generations of brains can be lost.

Q. But more and better science is still being done, right?

A. I believe that fundamental biology and the basic sciences overall are in danger. Science involves isolating yourself and working very hard. You have to be able to read more than two pages at a time and work more than eight or nine hours at a stretch. We now see that young students have more and more trouble concentrating or working long hours.

Q. Do you see a solution to this problem?

A. No. I think we all and especially young people need to ask ourselves what kind of world we want to live in. I think kids in rich countries are going to realize that, if they dont change their attitude, theyll be digging their own graves.

Follow this link:
Dr. Emmanuelle Charpentier: We all need to ask ourselves what kind of world we want to live in - EL PAS USA

ProLynx LLC

SAN FRANCISCO, Sept. 20, 2022 (GLOBE NEWSWIRE) --

ProLynx, Inc., a biotechnology company with a novel platform technology for half-life extension of therapeutics, enabling novel and potentially best-in-class treatments to be developed, today announced that Richard King, MBA, has been appointed as Chief Executive Officer and as a member of the Board of Directors. Additionally, Chris Ehrlich, MBA, has joined the company as a member of the Board of Directors.

As a seasoned executive in the industry with a track record of success in partnering, Richard is an excellent fit forProLynx,saidBill Rutter,a ProLynx Board member. The ProLynx Board looks forward to working with Richard and the executive team to realize the promise of our innovative technology for the betterment of patient and caregiver lives. Additionally, I am delighted to welcome Chris to the Board. His expertise in venture capital, business development and financing strengthen the capabilities of our Board.

Richard King is an accomplished executive with over 35 years of leadership experience in the biotechnology and pharmaceutical industries. He has raised over $1bn in private and public capital, completed multiple business transactions, including the sale of Tercica, Inc., the partnership of AcelRx and Grunenthal regarding a novel pain management system, and the strategic affiliation of CALIBR with the Scripps Research Institute.

I am delighted to join ProLynx at this time, saidRichard King. The ProLynx technology is incredibly unique, enabling half-life extension of proteins, peptides and small molecules. This advancement can make existing medications more effective, better tolerated and require less frequent administration. The ProLynx technology can also be applied to molecules in development that might otherwise never be advanced due to efficacy or toxicity issues, allowing these product candidates to move forward and possibly become life-altering treatments for patients.

Story continues

Chris Ehrlich began his career with consulting firm LEK before becoming a business development executive in the pharmaceutical industry. Subsequently he was Managing Director at venture capital firm InterWest, serving on multiple company Boards. He joined Locust Walk, a life sciences transaction firm, where, as Global Head of Biotechnology and Head of Strategic Transactions, he sourced and lead multiple transactions for emerging biopharmaceutical companies.

ProLynx is in a great position with its lead development program in clinical trials to treat various cancers, as well as multiple other programs having demonstrated proof of concept across a variety of disease areas, said Chris Ehrlich. I am delighted to join the Board to help bring this novel half-life extension technology forward to advance treatment options for patients in need.

AboutProLynx

ProLynx is a biotechnology company located in San Francisco, CA, developing proprietary drug delivery technologies for half-life extension of therapeutics. The ProLynx pipeline centers on a long-acting oncology drug, PLX038, in Phase 2 clinical trials, a long-acting interleukin 15, PLX015, for immuno-oncology and a very long-acting C-type natriuretic peptide, PLX138, for achondroplasia, together with several other early-stage programs.

Contact

Richard KingRichard@prolynxinc.com

Read more:
ProLynx appoints Richard King as Chief Executive Officer and Chris Ehrlich as Board Director - Yahoo Finance

As the world gets warmer, the use of power-hungry air conditioning systems is projected to increase significantly, putting a strain on existing power grids and bypassing many locations with little or no reliable electric power. Now, an innovative system developed at MIT offers a way to use passive cooling to preserve food crops and supplement conventional air conditioners in buildings, with no need for power and only a small need for water.

The system, which combines radiative cooling, evaporative cooling, and thermal insulation in a slim package that could resemble existing solar panels, can provide up to about 19 degrees Fahrenheit (9.3 degrees Celsius) of cooling from the ambient temperature, enough to permit safe food storage for about 40 percent longer under very humid conditions. It could triple the safe storage time under dryer conditions.

The findings are reported today in the journal Cell Reports Physical Science, in a paper by MIT postdoc Zhengmao Lu, Arny Leroy PhD 21, professors Jeffrey Grossman and Evelyn Wang, and two others. While more research is needed in order to bring down the cost of one key component of the system, the researchers say that eventually such a system could play a significant role in meeting the cooling needs of many parts of the world where a lack of electricity or water limits the use of conventional cooling systems.

The system cleverly combines previous standalone cooling designs that each provide limited amounts of cooling power, in order to produce significantly more cooling overall enough to help reduce food losses from spoilage in parts of the world that are already suffering from limited food supplies. In recognition of that potential, the research team has been partly supported by MITs Abdul Latif Jameel Water and Food Systems Lab.

This technology combines some of the good features of previous technologies such as evaporative cooling and radiative cooling, Lu says. By using this combination, he says, we show that you can achieve significant food life extension, even in areas where you have high humidity, which limits the capabilities of conventional evaporative or radiative cooling systems.

In places that do have existing air conditioning systems in buildings, the new system could be used to significantly reduce the load on these systems by sending cool water to the hottest part of the system, the condenser. By lowering the condenser temperature, you can effectively increase the air conditioner efficiency, so that way you can potentially save energy, Lu says.

Other groups have also been pursuing passive cooling technologies, he says, but by combining those features in a synergistic way, we are now able to achieve high cooling performance, even in high-humidity areas where previous technology generally cannot perform well.

The system consists of three layers of material, which together provide cooling as water and heat pass through the device. In practice, the device could resemble a conventional solar panel, but instead of putting out electricity, it would directly provide cooling, for example by acting as the roof of a food storage container. Or, it could be used to send chilled water through pipes to cool parts of an existing air conditioning system and improve its efficiency. The only maintenance required is adding water for the evaporation, but the consumption is so low that this need only be done about once every four days in the hottest, driest areas, and only once a month in wetter areas.

The top layer is an aerogel, a material consisting mostly of air enclosed in the cavities of a sponge-like structure made of polyethylene. The material is highly insulating but freely allows both water vapor and infrared radiation to pass through. The evaporation of water (rising up from the layer below) provides some of the cooling power, while the infrared radiation, taking advantage of the extreme transparency of Earths atmosphere at those wavelengths, radiates some of the heat straight up through the air and into space unlike air conditioners, which spew hot air into the immediate surrounding environment.

Below the aerogel is a layer of hydrogel another sponge-like material, but one whose pore spaces filled with water rather than air. Its similar to material currently used commercially for products such as cooling pads or wound dressings. This provides the water source for evaporative cooling, as water vapor forms at its surface and the vapor passes up right through the aerogel layer and out to the environment.

Below that, a mirror-like layer reflects any incoming sunlight that has reached it, sending it back up through the device rather than letting it heat up the materials and thus reducing their thermal load. And the top layer of aerogel, being a good insulator, is also highly solar-reflecting, limiting the amount of solar heating of the device, even under strong direct sunlight.

The novelty here is really just bringing together the radiative cooling feature, the evaporative cooling feature, and also the thermal insulation feature all together in one architecture, Lu explains. The system was tested, using a small version, just 4 inches across, on the rooftop of a building at MIT, proving its effectiveness even during suboptimal weather conditions, Lu says, and achieving 9.3 C of cooling (18.7 F).

The challenge previously was that evaporative materials often do not deal with solar absorption well, Lu says. With these other materials, usually when theyre under the sun, they get heated, so they are unable to get to high cooling power at the ambient temperature.

The aerogel materials properties are a key to the systems overall efficiency, but that material at present is expensive to produce, as it requires special equipment for critical point drying (CPD) to remove solvents slowly from the delicate porous structure without damaging it. The key characteristic that needs to be controlled to provide the desired characteristics is the size of the pores in the aerogel, which is made by mixing the polyethylene material with solvents, allowing it to set like a bowl of Jell-O, and then getting the solvents out of it. The research team is currently exploring ways of either making this drying process more inexpensive, such as by using freeze-drying, or finding alternative materials that can provide the same insulating function at lower cost, such as membranes separated by an air gap.

While the other materials used in the system are readily available and relatively inexpensive, Lu says, the aerogel is the only material thats a product from the lab that requires further development in terms of mass production. And its impossible to predict how long that development might take before this system can be made practical for widespread use, he says.

This work "represents a very interesting and novel system integration approach of passive cooling technologies," says Xiulin Ruan, a professor of mechanical engineering at Purdue University, who was not associated with this research. Ruan adds, "By combining evaporative cooling, radiative cooling, and insulation, it has a better cooling performance and can be effective in a wider range of climates than evaporative cooling or radiative cooling alone. The work could attract significant practical applications, such as in food preservation, if the system can be made at reasonable cost."

The research team included Lenan Zhang of MITs Department of Mechanical Engineering and Jatin Patil of the Department of Materials Science and Engineering.

Read the original here:
Passive cooling system could benefit off-grid locations - MIT News

Anderson, South Carolina--(Newsfile Corp. - September 20, 2022) - JZZ Technologies Inc.'s (OTC Pink: JZZI) ("JZZ" or the "Company")newly created digital marketing division has added 28 million new records to its database for marketing to U.S. healthcare products consumers.

JZZ Technologies, Inc. has acquired marketing data for more than 28 million U.S. healthcare product consumer records as part of its ongoing data acquisition efforts. These new records will be offered to Active Lifestyle Marketing customers as part of the Company's emerging marketing suite of products that includes 30+ million seniors, medical professionals, B2B contacts, 17 million metaverse users and now, 28 million healthcare products consumers.

The deal with a third-party provider requires that JZZ Technologies participate in a structured data sharing plan whereby JZZ and the data provider exchange records.

Email direct marketing is still considered among the most effective forms of digital advertising and the medical consumer segment offers one of the best yields in the industry. According to the digital marketing analysis group Wordstream, healthcare advertisers pay an average cost per click of $3.17 for ads through digital platforms. That compares to the average across all industries which is just $2.32 per click.

Using the comparable models for pricing, JZZ expects that its new record set can potentially generate up to an average of $315,000 per send. That is based on delivering a .5% click rate utilizing the entire new database with a 75% in-box delivery rate. The click rate may be higher or lower depending on individual marketing messages and other factors.

Charles Cardona, CEO of JZZ technologies, Inc. stated, "We will continue to broaden our product selection for Active Lifestyle Digital Media products as possible. The medical products consumers segment is naturally aligned with our audience of adults 55+ and it's a great source for digital income. We plan to focus on this segment as much as possible to maximize our potential for revenue."

Story continues

"We are beginning to generate revenue from our database with major digital service providers and that will start to really bear fruit in the next quarter," Cardona adds.

JZZ currently holds data sets for active adults age 55+, medical professionals, veterans, B2B contacts and many other segments. The total database of records owned and/or licensed by JZZ Technologies now equals roughly 70 million records. The Active Lifestyle Marketing division is continuing to segment the targeted data to include specific verticals such as individuals with diabetes, aging issues, and insurance consumers, among others.

About JZZ Technologies, Inc.

JZZ Technologies, Inc. is a diversified technology company engaged in digital media business which includes online media and apps (activelifestylemedia.com), content creation, and digital marketing, targeted to active adults 55+, strategic biotechnology and bioscience related to Human Life Extension and quality of life businesses that support improved quality of life for the aging population. For more information, please visit http://www.jzztechnologies.com.

Press Contacts:JZZ Technologies, Inc.Charles Cardona, CEOccardona@jzztechnologies.com

DISCLAIMER and FORWARD-LOOKING STATEMENTS

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, and such Forward-Looking Statements are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to the viability of the Company's business plans, the effect of acquisitions on our profitability, the effectiveness, profitability, and the marketability of the Company's products; the Company's ability to protect its proprietary information; general economic and business conditions; and the volatility of the Company's operating results and financial condition. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates, and projections about the Company and the industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances or to changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, management cannot assure the public that their expectations will turn out to be correct. Investors are cautioned that actual results may differ materially from the anticipated results.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/137718

Link:
JZZ Technologies, Inc. Adds 28 Million Healthcare Products Consumer Records to Its Active Lifestyle Media Marketing Database - Yahoo Finance

NorthStar Earth & Space

NorthStar Earth & Space

NorthStar Earth & Space (NorthStar) and Astroscale announce today, at the 2022 International Astronautical Congress (IAC) in Paris, that they are forming a strategic partnership to further support space sustainability by combining NorthStars precise space-based resident space object tracking with Astroscales enhanced spacecraft navigation and capture capability for on-orbit servicing.

Under this agreement, Astroscale and NorthStar will leverage their respective know-how, expertise, and unique services to highlight their shared commitment to space sustainability. Together, NorthStar and Astroscale will cooperate to demonstrate the benefits of combining precise In-Space Situational Awareness (ISSA) services to support reliable on-orbit servicing in low Earth orbit.

In 2023, NorthStar will launch the first commercial Space Situational Awareness service to deliver higher precision detection, tracking, and coverage for all near-Earth orbital regimes. NorthStars Space Information and Intelligence (Si2) services will serve all satellite operators to better manage their fleets, enhance spaceflight safety, and ensure space sustainability.

Astroscale is advancing its End-of-Life Services, most recently tested during its ELSA-d mission, which successfully magnetically captured its demonstration client spacecraft in August 2021. The latest ELSA-M servicer is in rapid development for launch in 2024 in partnership with OneWeb, the UK Space Agency and the European Space Agency. The state-of-the-art ELSA-M servicer will capture and retire multiple client spacecraft during a single mission. This collaboration will advance specific ISSA services required to support the tracking and capture of the Client spacecraft, as well as provide essential space-safety information about other space objects in orbit. Astroscale will endeavour to partner with NorthStar as a supplier of SSA services for future Astroscale missions.

NorthStar is proud to join forces with Astroscale as part of an essential community that is committed to advancing innovation and commercial services for space sustainability, said Stewart Bain, CEO & Founder of NorthStar Earth & Space. Combining NorthStars space-based coverage with Astroscales impressive on-orbit servicing capabilities is a very powerful response to immediate challenges in all near-Earth orbits

Were delighted to announce this partnership with NorthStar to develop our in-space situational awareness technology and data, said Nick Shave, Managing Director of Astroscale Ltd. We see an opportunity to enhance our spacecraft servicer and client satellite navigation & tracking capability with support from Northstars Space Information and Intelligence Services. Were keen to leverage our Rendezvous and Proximity Operations (RPO) and satellite capture expertise and advance our commercial on-orbit debris removal services with the benefit of both ground derived and in-space data. This is a great partnership that we look forward to harnessing with our forthcoming ELSA-M mission to clean up space and protect our orbital environment for future generations.

About NorthStarNorthStar seeks to empower humanity to preserve our planet through a unique Space and Earth information & intelligence platform using space-based sensors. NorthStar strives to help transform the way governments, industry and institutions assess risk, enforce regulations and make decisions to foster the sustainable development of our earth and space environment.

NorthStars unique space-based commercial Space Situational Awareness services address many of the critical and immediate challenges facing all satellite operators. Striving to see every object in every orbit, NorthStar will deliver more frequent and precise observations of resident space objects than any current system. Through a suite of high-speed decision quality information services derived from its unparalleled coverage, object custody, and enhanced predictive analytics NorthStar generates its Space Information & Intelligence services.

NorthStars investors comprise a global coalition of strategic partners, including Telesystem Space (a co-enterprise of the Sirois family office, Telesystem and the Rogers Family Trust of Canada), the Space Alliance of Europe (Thales Alenia Space and Telespazio), the Government of Quebec, the Government of Canada and the Luxembourg Future Fund. NorthStar Earth & Space head offices are located in Montral, Canada, its U.S. subsidiary, NorthStar Earth & Space Systems, Inc. is headquartered in McLean, Virginia and its European subsidiary, NorthStar Earth & Space Europe S. r.l. is headquartered in Luxembourg.

https://northstar-data.com/

About AstroscaleAstroscale is the first private company with a vision to secure the safe and sustainable development of space for the benefit of future generations, and the leading company dedicated to on-orbit servicing across all orbits.

Founded in 2013, Astroscale is developing innovative and scalable solutions across the spectrum of on-orbit servicing, including in-space situational awareness, end-of-life, and active debris removal and life extension, to create sustainable space systems and mitigate the growing and hazardous build-up of debris in space. Astroscale is also defining business cases and working with government and commercial stakeholders to develop norms, regulations, and incentives for the responsible use of space.

Headquartered in Japan, Astroscale has an international presence with subsidiaries in the United Kingdom, the United States, Israel, and Singapore.

Astroscale is a rapidly expanding venture company, working to advance safe and sustainable growth in space and solve a growing environmental concern.

Find out more at http://www.astroscale.com

The rest is here:
Astroscale and NorthStar Partner to Develop In-Space Technology to Support Space Sustainability - Space Ref

Proactive

Sydney, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:

EQ Resources Ltd (ASX:EQR) has delivered a significant increase in its Mt Carbine ore reserve and a substantial decrease in strip ratio, which improves mine life extension potential for Australias only primary tungsten producer.Click here

Radiopharm Theranostics Ltd (ASX:RAD) shares were trading 9% higher intra-day, at 18 cents, after securing a rare paediatric disease (RPD) designation for its DUNP19 technology for treating osteosarcoma by the US Food & Drug Administration (FDA).Click here

West Wits Mining Ltd (ASX:WWI)s preliminary trade-off studies as part of the Witwatersrand Basin Project (WBP) Project 200 initiative have confirmed the merits of progressing to a further scoping study.Click here

SenSen Networks Ltd (ASX:SNS, OTCQB:SNNSF) has delivered accelerating growth over the 2022 financial year, with operating results reflecting continued investments to support the companys rapid, ongoing vertical and geographic expansion, according to a report by Edison Research.Click here

Anson Resources Ltd (ASX:ASN) has added $50 million to the coffer for its Paradox Lithium Project in Utah, USA after securing binding commitments from institutional and sophisticated investors for a single tranche placement.Click here

Nova Minerals Ltd (ASX:NVA, OTCQB:NVAAF) and its 37%-owned affiliate Snow Lake Lithium have completed a further 20,000 metres of drilling at the Snow Lake Lithium Project in Manitoba, Canada, tripling the amount of drilling data that can be leveraged for an upcoming resource upgrade.Click here

New Century Resources Ltd (ASX:NCZ) has enhanced its board and management skillset with the appointment of senior resource industry professional Robert Cooper as its new managing director and CEO.Click here

Ora Banda Mining Ltd (ASX:OBM) will lose Keith Jones as a member of its board of directors as he plans to retire at the end of the month after more than three years with the company.Click here

Galena Mining Ltd (ASX:G1A) has achieved 83% construction progress as of August 31, 2022 at its Abra Base Metals Mine, situated in the Gascoyne region of Western Australia.Click here

Antipa Minerals Ltd (ASX:AZY) will receive a further $1 million boost to its capital-raising exercise as major shareholder Newcrest Mining Ltd intends to exercise its top-up right to maintain its 9.9% shareholding in the mineral exploration company.Click here

Lanthanein Resources Ltd (ASX:LNR)'s maiden drill campaign at the Lyons rare earths project, which started this week, is partially complete.Click here

ioneer Ltd (ASX:INR, OTC:GSCCF) has successfully completed a Technology System Supply Agreement with Caterpillar, the worlds largest manufacturer of construction and mining equipment and a leader in developing autonomous technology.Click here

Euro Manganese Ltd (ASX:EMN, TSX-V:EMN, OTCQX:EUMNF) has now filed two important instruments in the development of its Chvaletice Manganese Project in the Czech Republic.Click here

Strickland Metals Ltd (ASX:STK) has secured $1.225 million in funding in this latest share purchase plan (SPP), taking the company a step closer to its capital raising goal of $7 million.Click here

Duke Exploration Ltd (ASX:DEX) has received final assays from the reverse circulation (RC) drilling program it started in February at its flagship Bundarra Project.Click here

Story continues

About Proactive

Proactive is a unique tech-enabled platform providing companies globally with a comprehensive investor engagement solution across their business lifecycle.

With six offices on three continents, Proactive works with innovative growth companies quoted on the worlds major stock exchanges, helping executives to engage intelligently with investors.

In 2020, Proactive featured in 809 million search results, our content was viewed over 165 million times and our readers spent over 10 million hours on our websites. Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.

For more information on how Proactive can help you make a difference, email us at action@proactiveinvestors.com

Read the original here:
Proactive news headlines including EQ Resources, Radiopharm Theranostics, West Wits Mining and SenSen Networks - Yahoo Finance

VANCOUVER, BCandTORONTO, Sept. 16, 2022 /PRNewswire/ - Agnico Eagle Mines Limited (TSX: AEM) (NYSE: AEM) ("Agnico Eagle") and Teck Resources Limited (TSX: TECK.A) (TSX: TECK.B) (NYSE: TECK) ("Teck") announced today that Agnico Eagle has agreed to subscribe for a 50% interest in Minas de San Nicols, S.A.P.I. de C.V. ("MSN"), a wholly-owned Teck subsidiary which owns the San Nicols copper-zinc development project located in Zacatecas, Mexico (the "Transaction"). As a result of the Transaction, Teck and Agnico Eagle will become 50/50 joint venture partners at San Nicols.

"San Nicols is a high-quality project, located in a leading mining jurisdiction, with high grades, extremely competitive capital intensity, and first quartile costs," said Don Lindsay, President and CEO of Teck. "The opportunity to add the operating and development experience of Agnico Eagle should generate substantial benefits for the project including for all stakeholders throughout the project life cycle."

"This is a unique opportunity to create a long-term partnership between two high quality mining companies working together to de-risk and optimize a world class VMS deposit in a premier mining jurisdiction," added Ammar Al-Joundi, President and CEO of Agnico Eagle. "Agnico Eagle's project development, permitting and construction experience in Mexico, combined with Teck's base metals expertise, operating excellence and marketing leadership, are complementary skillsets and will contribute to the timely and successful development and operation of San Nicols."

Transaction Highlights

San Nicols Project Highlights

San Nicols Study Status

A detailed plan to complete a feasibility study, permitting, and community engagement has been developed, with initial work underway since January 2022. Further, an environmental and social baseline survey, including in-depth archaeological surveys and clearances, was carried out by Teck from 2018 to 2021. Well-developed community engagement and investment programs have resulted in strong support for development from stakeholders near the project and more broadly in Zacatecas.

The feasibility study is expected to be completed early in 2024 with project sanction thereafter subject to receipt of permits.

About the Transaction

Agnico Eagle will subscribe for US$580 million in MSN shares, through a wholly-owned Mexican subsidiary of Agnico Eagle, giving Agnico Eagle a 50% interest in MSN. The subscription proceeds received from Agnico Eagle will be used by MSN to fund the first US$580million of post-closing costs with subsequent funding to be contributed according to each partner's ownership percentage. Agnico Eagle's contributions will be made as study and development costs are incurred there is no up-front payment from Agnico Eagle. The US$580million share subscription implies a notional US$290million acquisition cost to Agnico Eagle for 50% of the San Nicols project plus the contribution by Agnico Eagle of 50% of the first US$580million of project costs for its own account.

Funding requirements beyond this initial subscription amount will be funded by Teck and Agnico Eagle in proportion to their shareholdings in MSN. The shareholders' agreement will include provisions typical in a transaction of this nature, as well as remedies for material breach that include accelerated dilution and forced sale of a defaulting shareholder's ownership interest. For governance purposes, Agnico Eagle will be deemed a 50% shareholder of MSN from closing, regardless of the number of shares that have been issued to Agnico Eagle.

Closing of the Transaction is subject to customary conditions precedent, including receipt of necessary regulatory approvals, and is expected to occur in the first half of 2023.

Additional Information on the San Nicols Project

For further details on the San Nicols project, please refer to the Supplemental Information slides in the Investors section of Teck's website (https://www.teck.com/investors/events-&-presentations/presentations-webcasts/supplemental-information-for-investors).

About Teck

As one of Canada's leading mining companies, Teck is committed to responsible mining and mineral development with major business units focused on copper, zinc, and steelmaking coal, as well as investments in energy assets. Copper, zinc, and high-quality steelmaking coal are required for the transition to a low-carbon world. Headquartered in Vancouver, Canada, Teck's shares are listed on the Toronto Stock Exchange under the symbols TECK.A and TECK.B and the New York Stock Exchange under the symbol TECK. Learn more about Teck atwww.teck.comor follow@TeckResources.

About Agnico Eagle

Agnico Eagle is a senior Canadian gold mining company, producing precious metals from operations in Canada, Australia, Finland, and Mexico. It has a pipeline of high-quality exploration and development projects in these countries as well as in the United States and Colombia. Agnico Eagle is a partner of choice within the mining industry, recognized globally for its leading environmental, social and governance practices. The Company was founded in 1957 and has consistently created value for its shareholders, declaring a cash dividend every year since 1983.

Forward Looking Statements

This news release contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information as defined in the Securities Act (Ontario). Forward-looking statements and information can be identified by statements that certain actions, events or results "could", "may", "might", "should", "will" or "would" be taken, occur or achieved. Forward-looking statements in this news release include statements regarding the expectation that the Transaction will close and the timing of closing; the expectation that the San Nicols project will be developed into production; the expected timing of first production; the estimated mine life; the expectation that there is meaningful mine life extension and regional exploration potential; the expected ownership interests of Teck and Agnico Eagle in the joint venture at any time; the expected production over the first five years of operation; all San Nicols project economics included in this news release, including head grades, average C1 operating costs, development capital cost estimate, payback period and IRR; the expectations as to results of the feasibility study, including development capital cost estimate, payback period and IRR; the statement that the project has been de-risked; and timing of project sanction decision.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Teck, Agnico Eagle or the joint venture to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause actual results to vary include, but are not limited to, changes in general economic conditions or commodity prices, unanticipated permitting, development or construction issues including delays in receiving permits or other regulatory approvals, or withdrawal or suspension of permits, unanticipated geotechnical conditions or other factors affecting construction plans and budgets including supplier, transportation, logistics or labour issues, adverse weather or natural disaster, community unrest, access issues, failure of plant and equipment, disruption of financial markets, the accuracy of our mineral estimates (including with respect to size, grade and recoverability) and the geological, operations and price assumptions on which these are based, other circumstances interfering with the closing of the Transaction, including an inability to satisfy the conditions to closing, including receipt of any regulatory approvals and failure by Teck or Agnico Eagle to fund as required by the agreements. Economic projections for the San Nicols project are presented on a 100% basis and, except as otherwise noted, assume US$3.50/lbcopper, US$1.15/lbzinc, US$1,550/oz gold, and US$20/oz silver.

Teck and Agnico Eagle caution you that the foregoing list of important factors and assumptions is not exhaustive. Other events or circumstances could cause actual results to differ materially from those estimated or implied by these forward-looking statements. Certain of these risks are described in more detail in the Annual Information Form of Teck and/or Agnico Eagle and in their respective subsequent quarterly report filings with Canadian securities administrators and the US Securities and Exchange Commission. Neither Teck nor Agnico Eagle assumes the obligation to revise or update these forward-looking statements after the date of this news release or to revise them to reflect the occurrence of future unanticipated events, except as maybe required under applicable securities laws.

SOURCE Agnico Eagle Mines Limited

Original post:
Teck and Agnico Eagle Announce Agreement on the San Nicols Copper-Zinc Project located in Zacatecas, Mexico - PR Newswire

Russias cutting-edge war machine, the MiG-31, capable of firing deadly hypersonic missiles, demonstrated its firing capabilities in the upper reaches of the atmosphere.

Russian Su-35 Fighter Demolished Ukrainian Air Defense Radar By Firing Anti-Radiation Missile, Moscow Says

Officials in the Russian Navys Baltic Fleet recently announced that Russian MiG-31 fighter jets practiced missile attacks during maneuvers in the stratosphere on September 13, Russian media Pravda reported. The Baltic fleet is headquartered at Kaliningrad.

The pilots of MiG-31 aircraft practiced flight maneuvers in the stratosphere, trained their skills to escape attacks from mock enemy aircraft and relocate to operational airfields of the region, said the statement from the Baltic Fleet.

In February, EurAsian Times reported that Russia had reportedly stationed a MiG-31K Foxhound fighter jet armed with a Kinzhal hypersonic land-attack missile in Kaliningrad along the Baltic Coast. The deployment was made days before the Russian troops launched their so-called special military operations.

Later, the Russian Ministry of Defense announced on August 18 the deployment of three MiG-31 fighters armed with Kinzhal hypersonic missiles to Chkalovsk airfield in the Kaliningrad Region as part of additional strategic deterrence measures.

According to reports, the three aircraft were moved to the Kaliningrad area for the exercises, where they simulated strikes on mock-up enemy command centers as part of training flights. The flights of the MiG-31 aircraft took place under the cover of Su-27 fighters.

It is pertinent to note that the Baltic region in Eastern Europe has seen hyper-vigilance from Moscow and the West in the aftermath of the invasion. When the Russian invasion began, the US sent its fighter jets to the Baltic for NATOs air policing missions.

MiG-31s are not frequently stationed at Russias Kaliningrad location. Some of the 50 aircraft stationed at the facility are older Su-27 and Su-24 fighters, with some newer Su-30SM and Su-35S jets on the way. According to reports, Iskander missiles are also housed in the enclave.

Besides the MiG-31 fighter jet, Russian reports indicated that the crews of the Eleron and Orlan-10 unmanned aerial vehicles of the Baltic Fleet practiced the tactics to overcome the air defense zone of a mock enemy at the Kaliningrad enclave.

While the MiG-31 drills are significant as they come during a surprising counter-offensive by Ukraine, it is not the first time this mighty warplane conducted exercises in the stratosphere. The MiG-31 had practiced in the stratosphere as early as 2017.

Further, in August 2019, the crews of upgraded MiG-31BM fighter jets held their first-ever dogfight in the stratosphere at an altitude of over 20 kilometers, as previously reported by TASS.

The two-seat MiG-31, known as the Foxhound under its NATO designation, is Russias primary fighter-interceptor aircraft. It has two D-30F6 engines, which help the aircraft have a base range of 1900 miles and a top speed of Mach 3 at high altitudes.

The MiG-31 is equipped with the SBI-16 Zaslon fixed phased array antenna radar, one of the most advanced in the world, to support its long-range and high-altitude air defense duty. The MiG-31 can engage air targets with various long and short-range missile combinations in addition to its Gsh-6-23 23mm gun.

The Russian Defense Ministry announced its plans to fund a MiG-31 Foxhound interceptor modernization and life extension program in July 2020. The MiG-31 can fly at high speeds and low altitudes, thanks to its sleek and aerodynamic body. The aircraft is built to track several targets at high altitudes simultaneously.

Despite Russias claims that it is developing the MiG-41 to replace the MiG-31, there is little evidence that the plane will be operational soon. Therefore, Russia has decided to develop several updated MiG-31 variants that will enable the Foxhound to continue service for many years. The MiG-31BM is the most notable of these.

The MiG-31BM is one of the MiG-31s most potent variants. It is a multipurpose, fast, long-range fighter with the power to destroy air and ground targets.

The MiG-31BM includes upgraded avionics, hands-on-throttle-and-stick (HOTAS) controls, liquid-crystal color multifunction displays (MFDs), a robust onboard computer system, digital data linkages, and phased array radar. It has the capability of intercepting 24 targets at once.

The MiG-31BM was initially intended to carry Kinzhal hypersonic missile, but MiG-31K was later selected as the carrier, according to Russian Defense Minister Sergei Shoigu. MiG-31Ks were used to strike targets early in Russias 2022 invasion of Ukraine with Kinzhals. Only 10 to 20 MiG-31Ks have beenupgradedto fire Kinzhals.

These Russian interceptor fighters have also intercepted NATO spy planes and fighter jets and will potentially continue to be deployed for a long time. In January,China-based Sohu publication had referred to the Russian MiG-31 interceptor fighter as a mysterious killer.

Read more:
Russias MiG-31 Fighter That Fired Hypersonic Missiles On Ukraine Conducted Drills In The Stratosphere - EurAsian Times

New York, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Space In-Orbit Refueling Market - A Global and Regional Analysis: Focus on Application, End User, Capability, and Country - Analysis and Forecast, 2022-2032" - https://www.reportlinker.com/p06317753/?utm_source=GNW 8 million by 2032 at a compound annual growth rate (CAGR) of 103.85% during the forecast period 2022-2032 (CAGR:2026-2032). The major factor driving the market growth is expected to be the increase in demand for sustainable and reusable space systems.

With the increasing number of satellites going into space, the demand for satellite servicing has been rising.In the future years, refueling capabilities are expected to become a need rather than an option for satellite operators.

Several market players have already started demonstrations and some have been successful. Commercial players are expected to extract the maximum benefit of the space in-orbit refueling technologies.

Market Lifecycle Stage

Space in-orbit refueling has been on the wishlist of satellite operators for decades, however, even though the concepts existed, no company was able to materialize the technology.However, in the past 5 years, multiple established players and startups have entered the market and are now full-fledged working on the refueling capabilities.

Massive amounts of investments are pouring into the industry and multiple collaborations are happening in order to co-develop new technologies.

Over 15 years of research and development on satellite refueling technologies have bought us to a stage where key players are performing successful demonstrations of in-orbit refueling and services in-orbit.Additionally, commercial players with large constellation sizes or heavy communication satellites are expected to adopt the market first.

Following this, government agencies like NASA and ESA are also stepping forward to develop technologies and fund startups in the in-orbit refueling industry.

Applications, such as site earth observation, communication, and navigation, are some of the areas where satellites are expected to be refueled in the coming years. Moreover, newer technologies, such as advanced docking systems, fueling ports, and artificial intelligence software are expected to support the growth of the space in-orbit refueling market over the 2022-2032 forecast period.

Market Segmentation:Segmentation 1: by Application Earth Observation Communication Navigation

Based on application, the space in-orbit refueling market is expected to be dominated by the communication segment owing to its technological and economic feasibility. Communication and Earth observation applications are expected to see the first initial missions for refueling.

Segmentation 2: by End-User Commercial Other End Users

Based on end-user, the space in-orbit refueling market is expected to be dominated by commercial end-users.Commercial end-users are expected to garner significant share and growth due to their priority requirement and economic feasibility.

Commercial satellite operators with large satellite constellations and heavy communication satellites are expected to adopt the technologies faster compared to any other segment.

Segmentation 3: by Region North America Europe Asia-Pacific

During the forecast period, North America is expected to dominate the space in-orbit refueling market (by region).The significant presence of key companies engaged in developing space in-orbit refueling services is a major factor responsible for the regions growth.

A higher number of collaborations between various service providers, satellite operators, and enabling technology providers is another factor driving the market growth. An increasing number of start-ups and emerging players and successful demonstrations and increasing investments by key players in the market are also contributing to the market growth.

Recent Developments in the Space In-Orbit Refueling Market

In January 2022, Astroscale Holdings Inc. and Orbit Fab, Inc signed a commercial agreement for refueling LEXI in the GEO orbit. LEXI is the first satellite that is designed to be refueled. As per the agreement, Orbit Fab, Inc will refuel Astroscales fleet of LEXI Servicers with up to 1000 kgs of Xenon Propellant. To develop technologies for cryogenic propellant storage and transfer, with these awards, NASA is investing in technologies for the storage and transfer of cryogenic propellants in space. Four awards worth more than $250 million went to companies working on cryogenic fluid management. To demonstrate refueling a GEO satellite, Northrop Grummans Mission Extension Vehicle-1 (MEV-1) docked with Intelsat 901 on 25th February 2020 and pushed the satellite back to its normal orbit. Northrop Grummans MEVs are expected to give more than 15 years of life extension to these satellites along with providing spacecraft inspections, inclination changes, and orbit repair. In April 2022, Washingtons Defense Innovation Unit (DIU) is planning to provide commercial refilling services in near the prime space real estate of Geosynchronous Orbit, commonly referred to as GEO. Its also planning on creating a bulk fuel depot in the orbits. DIU is looking for companies with the capability for bulk liquid and gas propellant storage (>5,000 kg) in orbit. Two of the propellants include hydrazine and liquid oxygen. In April 2022, Orbit Fab, Inc and Neutron Star Systems have announced a partnership for the co-development of sustainable propulsion capability and satellite refueling technologies. The agreement will help to increase the range of refuellable propellants by combining NSS propellant-agnostic electric propulsion technology with Orbit Fabs refueling interfaces and tankers.

Demand - Drivers and Limitations

Following are the drivers for the Space In-Orbit Refueling market: Increase in Demand for Sustainable and Reusable Space Systems Life Extension Services to Enable Other In-Orbit Services in Future

Following are the challenges for the Space In-Orbit Refueling market: High Operational Cost of Refueling Interface and Docking Regulatory Challenges Spacecraft Design Compatibility for Refueling Operations Storage and Transfer of Cryogenic Propellants in Space

Following are the opportunities for the Space In-Orbit Refueling market: Increase in Investments for Startups Rise in Demand for In-Space Services Advancement of New Space Technologies for Storage, Refueling, and Receiving Propellants

How can this report add value to an organization?

Product/Innovation Strategy: The product section will help the reader understand the different solutions for the space in-orbit refueling and services market, such as the type of capabilities and emerging technologies.It will also help readers understand the potential of the services at a global level and learn about their progress.

The players operating in these markets are developing innovative offerings and are deeply engaged in long-term agreements and contracts with commercial and government agencies. Moreover, the study also examines the investment scenario in the space in-orbit refueling and services market.

Growth/Marketing Strategy: The players operating in the space in-orbit refueling market are engaged in several strategies, including strategic partnerships, contracts, agreements, and business expansion. The marketing strategies will help the readers understand the revenue-generating strategies adopted by the in-orbit service providers operating in the space in-orbit refueling market.

For instance, Orbit Fab, Inc and the U.S. Air Force Research Laboratory have signed a technology-sharing agreement to share details regarding RAFTI. The company markets its products to all different layers of the military, intelligence, and commercial satellite community. The Air Force will help Orbit Fab review some of the technologies that aided in developing them. More specifically, they are going to advise on requirements and design elements, as well as provide testing and qualification access at several governmental facilities throughout the country.

In February 2022, Northrop Grumman-owned SpaceLogictics has signed a launch agreement with SpaceX and a contract with Optus for the sale of its Mission extension pod. Under the agreement, SpaceX will be responsible for providing launch services for the 2024 MRV and MEP launches.

Competitive Strategy: The study has analyzed and profiled the key service providers, start-ups, and emerging players in the space in-orbit refueling market.These companies capture the maximum share in the global space in-orbit refueling market.

Additionally, a detailed competitive benchmarking of the companies and organizations operating in the space in-orbit refueling market has been carried out, which will help the reader to understand the performance of the players, exhibiting a clear market landscape. In addition to this, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the potential revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies profiled in the study have been selected based on inputs gathered from primary experts and analysis of the companies product portfolios, key developments, and market penetration.

Space in-orbit refueling as a technology is still in the development and demonstration phase.However, there are several established players and startups that have entered the market and have made considerable progress.

Considering the present market scenario and future forecasts, the market is expected to grow at a CAGR of 103.85% by 2032.

Some prominent established names in this market are: Astroscale Holdings Inc. Altius Space Machines, Inc. D-Orbit SpA Lockheed Martin Corporation LMO Space Maxar Technologies Inc. Momentus Space Orbit Fab, Inc. Obruta Space Solutions Orbit Recycling SpaceX SpaceLogistics (a subsidiary of Northrop Grumman Corporation) Space Machines Company Starfish Space Inc. Tethers Unlimited, Inc.

Countries Covered North America U.S. Canada Europe Germany Russia France U.K. Rest-of-Europe Asia-Pacific India Japan Rest-of-Asia-PacificRead the full report: https://www.reportlinker.com/p06317753/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Originally posted here:
Space In-Orbit Refueling Market - A Global and Regional Analysis: Focus on Application, End User, Capability, and Country - Analysis and Forecast,...

Pune, Maharashtra, India, September 19 2022 (Wiredrelease) Prudour Pvt. Ltd :Global Stem Cell Banking Market: Introduction

Stem cells are capable of transforming into any kind of tissue or organ in the body. Stem cells are found in bone, bone marrow, fetal tissue, baby teeth, fat and human embryos. They can also be found in hair follicles, muscle and circulating blood. Cord blood is a great source of stem cell. Cord blood stem cells have several advantages. They are less likely to be rejected by the immune system during transfusions, and they can be more effective in transplant. Stem cell banking has seen an increase in demand due to numerous applications, including treatment for various diseases such as cancer. These stem cells are taken from the human body and stored for future usage.

The global stem cell banking market is projected to reach USD 9.42 billion by 2023 from USD 6.29 million in 2018, at a CAGR of 8.5% from 2018 to 2023.

Stem Cell Banking Market DynamicsThis section discusses market drivers, opportunities, limitations, and challenges. The following details are provided:

Drivers: Stem Cell Banking Requirements

The markets major drivers are the increase in the worldwide burden of major diseases and the increasing use of stem cell banking to cure severely damaged tissues. The markets growth is expected to be driven by the increased use of hematopoietic and brain stem cell transplantation procedures, as well as the rise in skin transplants and brain cells transplantations.

Surging Awareness

The market will benefit from awareness campaigns by both government and non-government agencies to promote stem cell therapy.

Opportunities: Growing Investments and Advancements

Market growth will be driven by the development and commercialization of new technologies that preserve, process, and store stem cells. Market growth opportunities will also be provided by increasing investments in stem-cell-based research.

Restraints/Challenges Global Stem Cell Banking Market: High-Cost

The high operating costs associated with stem cell transplantation are expected to slow down market growth.

In the 2022-2029 forecast period, stem cell banking will face challenges due to the stringent regulatory frameworks as well as socio-ethical concerns relating to embryonic stem cell.

Recent Developments

Life Cell International (India), has launched an improved and enhanced umbilical cord collection tool in 2017.

2017 saw Vita34 AG acquire Seracell Pharma AG (Germany), in order to consolidate its position within the German stem-cell banking market.

StemCyte India Therapeutics Pvt. Ltd. (India), which is a subsidiary of StemCyte US, received accreditation from The Foundation for the Accreditation of Cellular Therapy. It can provide stem cell banking services for private and public clients.

Cord Blood Registry, (US) signed an agreement with New York Stem Cell Foundation in 2015 to create induced pluripotent (SP) stem cells from umbilical chords.

Identify the key factors that will drive your companys growth. Request a brochure of this report here:https://market.us/report/stem-cell-banking-market/request-sample/

[Sample reports can be used to check out our detailed reports and study material before purchasing]

1. The updated 150+ page reports give an in-depth analysis and commentary on the COVID-19 virus pandemic.

2. You can find out about industry data and interviews with experts to learn more about topics like regional impact analysis, global outlook, competitive landscape analysis, market size, share, and the size of regional markets.

3. These reports are available in PDF format. You can view them on your computer or print them.

4. PDF sample report provides additional information on Major Market Players including their Sales Volume, Business Strategy, Revenue Analysis and Revenue Analysis. This gives readers an advantage over other people.

5. The Market.us Research report includes a detailed analysis of key factors that influence the markets growth.

6. Sample report also provides insight on major market players, their business strategies, and revenue analysis to give readers an edge over others.

Stem Cell Banking Market Competitive Landscape

CCBCCBRViaCordEsperiteVcanbioBoyalifeLifeCellCrioestaminalRMS RegrowCordlife GroupPBKM FamiCordcells4lifeBeikebiotechStemCyteCryo-cellCellsafe Biotech GroupPacifiCordAmericordKrioFamilycord

Competitive Benchmarking

Competitive benchmarking allows you to see how your competitors are doing and compare it to your companys. Market.us professionals assist our stakeholders in keeping track of competitors, identifying improvement areas, increasing profits, and designing better go-to-market strategies.

Interested in Procure The Data? Inquire here athttps://market.us/report/stem-cell-banking-market/#inquiry

Stem Cell Banking Market Segmentation

Based on the type, the Stem Cell Banking market is segmented into

Umbilical Cord Blood Stem CellEmbryonic Stem CellAdult Stem Cell

Based on the application, the Stem Cell Banking market is segmented into

Diseases TherapyHealthcare

Market Breakup by Region:

North America (United States, Canada)

Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)

Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)

Latin America (Brazil, Mexico, Others)

The Middle East and Africa

Market Report Coverageand Deliverables will help you to understand:

1. Company revenue shares | revenue (US$ Mn)

2. Upcoming Regional opportunities

3. Latest trends & Market dynamics

4. Competitive benchmarking

5. Key Financial Charts

Grab the full detailed report here:https://market.us/report/stem-cell-banking-market/

Key Questions Answered in This Report:

Q1. What is the market size of Stem Cell Banking?

Q2. What are the elements of retail Stem Cell Banking?

Q3. What are the key decision drivers for service buyers?

Q4. How can we accelerate our bidding process?

Q5. What is the potential of the Stem Cell Banking Market?

Q6. Who are the prominent players in Stem Cell Banking Market?

Q7. What are the different types of Stem Cell Banking market?

Q8. What are the top strategies that companies adopt in Stem Cell Banking Market?

Q9. What is the future of Stem Cell Banking?

Trending Reports (Book Now with Save 25% [Single User], 38% [Multi-User], 45% [Corporate Users] + Covid-19 scenario+ Impact of Russia-Ukraine war):

Fiber Grade Polylactice Acid Market Strategies [+Sales Growth], Factors and Forecast 2031

Ambient Light, IR, UV Sensor Market Potentially Growing Significant Business Opportunities to 2031

Testing, Inspection, And Certification TIC For Metals Market Segmentation, Operating Business Segments 2031

High-resolution Audio(audiophile audio) Market Globally Expected to Drive Growth [+Net Income] | 2022-2031

Corticosteroid-Responsive Dermatoses Market 2022 Covering Prime Factors and Competitive Outlook Till 2031

Get in Touch with Us :

Global Business Development Teams Market.us

Market.us (Powered By Prudour Pvt. Ltd.)

Send Email:inquiry@market.us

Address: 420 Lexington Avenue, Suite 300 New York City, NY 10170, United States

Tel: +1 718 618 4351

Website:https://market.us

Read Our Innovative Blogs @ https://enmovimientorevista.com/

This content has been published by Prudour Pvt. Ltd company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.

Link:
Stem Cell Banking Market to Cross USD 9.42 Bn; Short-term Decline to Be Witnessed amidst COVID-19 Pa - PharmiWeb.com

MIRAMAR, FL, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Stemtech Corporation (Stemtech) (OTCQB: STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, today announced creation of new stem cell skincare products.

Stemtech Corporation President and Chief Operating Officer, John W. Meyer, said the introduction of the stem cell skincare line is very exciting for us to offer our Independent Business Partners (IBPs) and customers. The product will be introduced at the upcoming Cancun, Mexico Incentive Meeting in December. Meyer continues to say that Stemtechs belief in highly efficacious and quality products expands into a very important area for youthful and healthy skin care. The skincare, along with our stemceutical products of RCM - stemrelease3, StemFlo Advanced and MigraStem, is a winning combination for inner health and outer radiance - fantastic! We all want to feel better, look better. By using Stemtech products, you can!

Fortune Business Insights in August 2021 published that the global skincare market is projected to grow from $100.13 billion in 2021 to $145.82 billion in 2028 at a CAGR of 5.52% in forecast period, 2021-2028. Meyer continues, noting while it may seem that there are many companies already in this space, Stemtech feels confident with our new science being developed, we will have a significant impact on the skincare market using our stem cell scientific knowledge.

Charles S. Arnold, Stemtech Corporation Chairman and CEO stated that the introduction of skincare focuses new Stemtech stem cell technology on skincare for healthier skin, the largest organ of the body, which we recognize as a key to anti-aging. Our excitement at being able to launch new products, complete with samples, for a more youthful and healthy skin will catapult our Field to new growth and revenue opportunities. We know our IBPs will be exuberant with this great new Stemtech Skincare product line.

About Stemtech Corporation

Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and in select international markets. The Companys patented formulas help the release, circulation and migration of the bodys adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3, Stemflo MigraStem, OraStem (Oral Health Care), and D-Fuze (EMF blocker). Its nutraceutical products are all-natural, plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit http://www.stemtech.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed onAugust 23, 2022. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.

http://www.Stemtech.com

Investor Relations: Investor Relations: 954-715-6000 ext 1040invrel@stemtech.com

Originally posted here:
STEMTECH CORPORATION ANNOUNCES THE INTRODUCTION OF A NEW - GlobeNewswire

Five people with the autoimmune condition lupus are now in remission after receiving a version of CAR-T therapy, which was originally developed for cancer

By Clare Wilson

Illustration of a CAR-T cell

CHRISTOPH BURGSTEDT/SCIENCE PHOTO LIBRARY

A high-tech cell therapy used to treat cancer has been repurposed as a treatment for lupus, an autoimmune condition that can cause joint, kidney and heart damage.

CAR T-cell therapy has put all five people with lupus treated so far into remission. The participants have been followed up for an average of 8 months, with the first person treated 17 months ago. Thats kind of unheard of, says Chris Wincup at Kings College London, who wasnt involved in the study. This is incredibly exciting.

But it is too soon to know how long the remissions will last, says Georg Schett at the University of Erlangen-Nuremberg in Germany, who was part of the study team.

CAR T-cells were developed to treat blood cancers that arise when B cells, a type of immune cell that normally makes antibodies, start multiplying out of control.

The approach requires taking a sample of immune cells from a persons blood, genetically altering them in the lab so they attack B cells and then infusing them back into the individuals blood. It seems to put 4 out of 10 people with these kinds of cancers into remission.

Lupus, also called systemic lupus erythematosus, is caused by the immune system mistakenly reacting against peoples own DNA. This is driven by B cells making antibodies against DNA released from dying cells.

It is currently treated with medicines that suppress the immune system or, in more severe cases, with drugs that kill B cells. But the treatments cant kill all the B cells, and if the disease flares up badly, some people develop kidney failure and inflammation of their heart and brain.

Schett and his team wondered whether using CAR T-cells to hunt down all the B cells would be more effective. Within three months of receiving the treatment, all five participants were in remission, without needing to take any other medicines to control their symptoms.

The CAR T-cells were barely detectable after one month, and after three and a half months, the volunteers B cells started to return, having been produced by stem cells in bone marrow. These new B cells didnt react against the DNA.

We dont know what normally causes B cells to start reacting against DNA in people with lupus, so it is possible that some kind of trigger may start the process happening again, says Wincup.

The achievement means CAR T-cells may also be useful against other autoimmune diseases that are driven by antibodies, such as multiple sclerosis (MS), in which the immune system attacks nerves, says Schett.

Another radical treatment for MS involves rebooting the immune system by destroying it with chemotherapy. By comparison, CAR T-cells would be less invasive and more tolerable, he says.

But it is too soon to know how effective CAR T-cells will be for autoimmune conditions, says Wincup. This is a small number of patients, so we dont know if this is going to be the result for everyone.

When used in cancer, CAR T-cells are expensive to create for each person, so they may only be used for autoimmune conditions in people with severe disease when no other treatments are available, he says.

Journal reference: Nature Medicine , DOI: 10.1038/s41591-022-02017-5

More on these topics:

Read the original post:
Radical lupus treatment uses CAR T-cell therapy developed for cancer - New Scientist

Esteemed award is an international forum celebrating noteworthy achievements in equine research and individuals who have significantly impacted equine health

The University of Kentucky (UK) Gluck Equine Research Center unveiled the 2022 inductees to the Equine Research Hall of Fame. The winners include Lisa Fortier, DVM, PhD, DACVS; Katrin Hinrichs, DVM, PhD; Jennifer Anne Mumford, DVM; and Stephen M. Reed, DVM.

The scientists were nominated by their fellow peers and past awardees. Nominees may be living or deceased, active in or retired from the field of equine research.

In research, we always stand on the shoulders of those who go before us with great discoveries. This years recipients have made substantial contributions that will ensure an excellent future for equine research, expressed Nancy Cox, UK vice president for land-grant engagement and College of Agriculture, Food and Environment dean, in a university release.1

The success of Kentuckys horse industry is inseparable from the decades of hard work by outstanding equine researchers, added Stuart Brown, chair of the Gluck Equine Research Foundation. Though impossible to measure, it is a unique privilege to recognize the impact made by these four scientists in advancing the health and wellbeing of the horse and, on behalf of the entire equine community, show our appreciation.

Below are the details of each awardee1:

Throughout the past 30 years, Fortier has been renowned for her substantial contributions in equine joint disease, cartilage biology, and regenerative medicine. Her research focuses on early diagnosis and treatment of equine orthopedic injuries to prevent permanent damage to joints and tendons. She is most well-known for her work in regenerative medicine, spearheading the use of biologics such as platelet rich plasma, bone marrow concentrate, and stem cells for use in horses and humans. Additionally, Fortiers lab has been key in strides associated with cartilage damage diagnosis and clinical orthopedic work.

Fortier achieved her bachelors degree and doctor of veterinary medicine degree from Colorado State University. She finished her residency at Cornell, where she also earned a PhD and was a postdoctoral fellow in pharmacology. Currently, she serves as the James Law Professor of Surgery at Cornells College of Veterinary Medicine. She is the editor-in-chief of the Journal of the American Veterinary Medical Association and serves on the Horseracing Integrity and Safety Authority Racetrack Safety Standing Committee.

Hinrichs dedicates her career to research mainly in equine reproductive physiology and assisted reproduction techniques. Her focus has consisted of equine endocrinology, oocyte maturation, fertilization, sperm capacitation, and their application to assisted reproduction techniques.

Her 40 years of research have resulted in various notable basic and applied research accomplishments. The applied achievements include generating the first cloned horse in North America and creating the medical standard for effective intracytoplasmic sperm injection and in vitro culture for equine embryo production. She has mentored over 85 veterinary students, residents, graduate students, and postdoctoral fellows in basic and applied veterinary research. Her laboratories have hosted about 50 visiting scholars worldwide.

Hinrichs achieved her bachelors degree and doctor of veterinary medicine degree from the University of California, Davis. She finished residency training in large animal reproduction at the University of Pennsylvanias New Bolton Center and received a PhD at the University of Pennsylvania.

Mumford is a posthumous inductee who received international respect as among the most prominent researchers of equine infectious diseases, specifically equine viral diseases. Her career at the Animal Health Trust, Newmarket, United Kingdom, began when she was deemed the first head of the newly established equine virology unit. Her work focused on the leading causes of acute infectious respiratory disease in the horse, mainly equine herpesvirus and equine influenza virus, and to a lesser extent,Streptococcus equi.

Mumford impacted several of these realms, including developing enhanced vaccines, diagnostics, and international surveillance. Additionally, she helped create research groups in the related fields of equine genetics and immunology.

Throughout Mumfords over 30 year-career, she helped the Animal Health Trust be recognized as one of the worlds leading centers for the study of the biology, epidemiology, immunology and pathology of diseases.

Reeds nominators deemed his as the last word in equine neurology. He is known as among the most prominent equine neurologists worldwide. His list of 180 peer-reviewed publications feature important contributions to equine medicine, neurology, physiology and pathophysiology. He has shared in his accomplishments as a mentor and role-model for hundreds of aspiring equine practitioners.

Reed received his bachelors degree and doctor of veterinary medicine degree from The Ohio State University. He finished his internship and residency training in large animal medicine at Michigan State University.

The UK Gluck Equine Research Foundation will induct the 4 winners into the UK Equine Research Hall of Fame October 26, 2022 at Kroger Field in Lexington, Kentucky.

Reference

Wiemers H. UK Equine Research Hall of Fame inductees announced. UK College of Agriculture, Food and Environment. News release. September 13, 2022. Accessed September 20, 2022. https://news.ca.uky.edu/article/uk-equine-research-hall-fame-inductees-announced-1

Read this article:
University of Kentucky Equine Research Hall of Fame announces awardees - DVM 360

Background: Male hypogonadism is a clinical and biochemical androgen insufficiency syndrome, becoming more prevalent with age. Exogenous testosterone is first-choice therapy, with several side effects, including negative feedback of the hypothalamic-pituitary-gonadal axis, resulting in suppression of intratesticular testosterone production and spermatogenesis. To preserve these testicular functions while treating male hypogonadism, clomiphene citrate is used as off-label therapy. This systematic review and meta-analysis aimed to evaluate the effectiveness and safety of clomiphene citrate therapy for men with hypogonadism.

Methods: The EMBASE, PubMed, Cochrane databases were searched in May 2021, for effectiveness studies of men with hypogonadism treated with clomiphene citrate. Both intervention and observational studies were included. The Effective Public Health Practice Project Quality Assessment Tool, a validated instrument, was used to assess methodological study quality. The primary outcome measure was the evaluation of serum hormone concentration. Secondary outcomes were symptoms of hypogonadism, metabolic and lipid profile, side effects, safety aspects.

Results: We included 19 studies, comprising four randomized controlled trials and 15 observational studies, resulting in 1642 patients. Seventeen studies were included in the meta-analysis, with a total of 1279 patients. Therapy and follow-up duration varied between one and a half and 52 months. Total testosterone increased with 2.60 (95% CI 1.82-3.38) during clomiphene citrate treatment. An increase was also seen in free testosterone, luteinizing hormone, follicle stimulating hormone, sex hormone-binding globulin and estradiol. Different symptom scoring methods were used in the included studies. The most frequently used instrument was the Androgen Deficiency in Aging Males questionnaire, whose improved during treatment. Reported side effects were only prevalent in less than 10% of the study populations and no serious adverse events were reported.

Conclusion: Clomiphene citrate is an effective therapy for improving both biochemical as well as clinical symptoms of males suffering from hypogonadism. Clomiphene citrate has few reported side effects and good safety aspects.

Keywords: clomiphene citrate; male hypogonadism; testosterone deficiency.

The rest is here:
Clomiphene citrate for men with hypogonadism: a systematic ... - PubMed

What is hypogonadism in females?

Hypogonadism in females describes the inadequate function of the ovaries, with impaired production of germ cells (eggs) and sex hormones (oestrogen and progesterone).

Hypogonadism in females is due to disruption of any section of the hypothalamicpituitaryovarian axis pathway (figure 1). In a correctly functioning hypothalamicpituitaryovarian axis pathway:

Figure 1. The hypothalamicpituitaryovarian axis pathway

Primary ovarian insufficiency and secondary hypogonadism may be congenital or acquired [1,2].

The main mechanism for congenital primary ovarian deficiency remains unknown in the majority of cases. Some cases relate to:

The causes of acquired primary ovarian insufficiency include:

Congenital secondary hypogonadism is gonadotrophin deficiency due to a genetic mutation, such as in Kallmann syndrome.

Acquired secondary hypogonadism can be due to damage to the pituitary/hypothalamus. Causes of acquired secondary hypogonadism can include:

Gonadotropins can be suppressed by:

The clinical features of hypogonadism depend on the age at presentation [3].

Symptoms of low oestrogen levels are rarely present in hypogonadism pre-puberty. The presenting features are absent pubertal development (reduced growth and absence of pubic hair) and primary amenorrhoea (absence of menarche).

After the completion of puberty, the features of hypogonadism include:

The long-term risks of oestrogen deficiency include an increased risk of osteoporosis and cardiovascular disease. The risk is greater with a younger age of onset. In contrast, the risk of breast cancer may be slightly reduced.

Oestrogen has a key role in maintaining skin health. Oestrogen helps maintain skin thickness and collagen levels, skin elasticity, and moisture. It is also thought to play a role in wound healing [4].

Low oestrogen levels are associated with:

Skin changes may also reflect the underlying cause of hypogonadism; for example, hyperpigmentation may be a sign of an autoimmune disease.

If hypogonadism is suspected following a detailed history and examination, the following investigation pathway can be followed.

Treatment of hypogonadism is directed at the underlying pathology where possible, helping the woman become fertile if desired, and preventing the long-term complications of hypoestrogenism (ie, osteoporosis, increased cardiovascular disease, and urogenital atrophy).

As a general rule, women of reproductive age with hypoestrogenism should receive hormone replacement therapy. Specialist input should be sought, as there are potential significant complications of hormone therapy, such as:

Post-menopause, hormone replacement therapy is indicated for significant symptoms.

See the original post:
Hypogonadism in females | DermNet

Aim: Symptomatic late-onset hypogonadism is associated not only with a decline in serum testosterone, but also with a rise in serum estradiol. These endocrine changes negatively affect libido, sexual function, mood, behavior, lean body mass, and bone density. Currently, the most common treatment is exogenous testosterone therapy. This treatment can be associated with skin irritation, gynecomastia, nipple tenderness, testicular atrophy, and decline in sperm counts. In this study we investigated the efficacy of clomiphene citrate in the treatment of hypogonadism with the objectives of raising endogenous serum testosterone (T) and improving the testosterone/estrogen (T/E) ratio.

Methods: Our cohort consisted of 36 Caucasian men with hypogonadism defined as serum testosterone level less than 300 ng/dL. Each patient was treated with a daily dose of 25 mg clomiphene citrate and followed prospectively. Analysis of baseline and follow-up serum levels of testosterone and estradiol levels were performed.

Results: The mean age was 39 years, and the mean pretreatment testosterone and estrogen levels were 247.6 +/- 39.8 ng/dL and 32.3 +/- 10.9, respectively. By the first follow-up visit (4-6 weeks), the mean testosterone level rose to 610.0 +/- 178.6 ng/dL (P < 0.00001). Moreover, the T/E ratio improved from 8.7 to 14.2 (P < 0.001). There were no side effects reported by the patients.

Conclusions: Low dose clomiphene citrate is effective in elevating serum testosterone levels and improving the testosterone/estradiol ratio in men with hypogonadism. This therapy represents an alternative to testosterone therapy by stimulating the endogenous androgen production pathway.

See the original post here:
Clomiphene citrate effects on testosterone/estrogen ratio in male ...

NEW YORK, Sept. 19, 2022 /PRNewswire/ --The male hypogonadism market has been segmented by type (Klinefelter syndrome, Kallmann syndrome, and pituitary disorders) and geography (North America, Europe, Asia, and Rest of World (ROW)). North America will account for 37% of the market's growth during the forecast period. This growth is attributed to factors such as the significant increase in the prevalence of male hypogonadism. Moreover, market growth in this region will be faster than the growth of the market in other regions. The US and Canada are the key countries for the male hypogonadism market in North America.

Themale hypogonadism market size is estimated to grow by USD 684.95 mn from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 5.09% during the forecast period.

Technavio provides a comprehensive report summary describing the market size and forecast along with research methodology. The FREE sample reportis available in PDF format

Company Profiles

The male hypogonadism market report includes information on the product launches, sustainability, and prospects of leading vendors, including AbbVie Inc., Aytu BioPharma Inc., Bayer AG, Bio Techne Corp., Diurnal Group Plc, Eli Lilly and Co., Endo International Plc, Ferring B.V., IBSA Institute Biochimique SA, Lipocine Inc., Merck and Co. Inc., Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. The key offerings of some of these vendors are listed below:

Technavio's reports provide key strategic initiatives used by vendors, along with key news and the latest developments. View our FREE PDF Sample Report Now

Competitive Analysis

The competitive scenario provided in the male hypogonadism market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.

Market Dynamics

Factors such as an increase in the incidence of hypogonadism and the increasing awareness about male hypogonadism and its treatment options will be crucial in driving the growth of the market. However, the loss of patent exclusivities and increasing generic competition will restrict the market growth.

Technavio has identified key trends, drivers, and challenges in the market, which will help vendors improve their strategies to stay ahead of their competitors. View our FREE PDF Sample Report

Related Reports

Sexually Transmitted Diseases (STD) Treatment Market by Service and Geography - Forecast and Analysis 2022-2026: The sexually transmitted diseases (STD) treatment market share is expected to increase by USD 13.48 billion from 2021 to 2026.

Sexual Enhancement Supplements Market by Product and Geography - Forecast and Analysis 2022-2026: The sexual enhancement supplements market share is expected to increase by USD 801.29 million from 2021 to 2026.

Male Hypogonadism Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 5.09%

Market growth 2022-2026

USD 684.95 million

Market structure

Fragmented

YoY growth (%)

3.52

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 37%

Key consumer countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

AbbVie Inc., Aytu BioPharma Inc., Bayer AG, Bio Techne Corp., Diurnal Group Plc, Eli Lilly and Co., Endo International Plc, Ferring B.V., IBSA Institute Biochimique SA, Lipocine Inc., Merck and Co. Inc., Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Market Dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse Health CareMarket Reports

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Type

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com

Website: http://www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/male-hypogonadism-market-size-to-grow-by-usd-684-95-mn-abbvie-inc-and-bayer-ag-among-key-vendors---technavio-301626163.html

SOURCE Technavio

Read the original here:
Male Hypogonadism Market Size to Grow by USD 684.95 Mn, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio - Longview News-Journal

With the intensified direct-to-consumer marketing of male sexual medicine treatments, the recent legislative changes in reproductive rights and their unknown long-term effect on assisted reproduction availability for infertile men, and the explosion of telehealth, the practice of male sexual medicine is evolving at a breakneck pace. Specialists in male sexual and reproductive medicine have been tasked with digesting the evolving literature and forming evidence-based treatment guidelines for men with erectile dysfunction, Peyronie disease, infertility, and a host of other conditions. Compared with other areas of urology and medicine in general, male sexual and reproductive medicine has a disappointingly small number of well-designed prospective studies, along with a significant gap in funding for male reproductive health compared with female reproductive health. Several manuscripts published in 2022 started to narrow this gap and provide valuable level 1 evidence supporting (or discounting) key areas within sexual medicine and infertility.

For men with severe male factor infertility and nonobstructive azoospermia, surgical intervention is often indicated to retrieve sperm. Testicular sperm aspiration (TESA) and microdissection testicular sperm extraction (mTESE) are 2 commonly used approaches. A recent study by Jensen et al compared the efficacy of these 2 approaches in one of the few prospective randomized-controlled trials in male infertility.1 In the study, 49 patients were randomly assigned to mTESE with a sperm retrieval rate of 43%, and 51 patients were randomly assigned to TESA with a sperm retrieval rate of 22%. Men with failed TESA then went on to salvage mTESE with a combined sperm retrieval rate of 29%. Participants in the mTESE arm, however, had decreased postoperative testosterone levels, and 24% of participants experienced de novo hypogonadism at 6 months. Prior literature has suggested the testosterone drop is transient and that it will likely recover by 12 months. In summary, the study results showed that mTESE remains the gold standard for treatment of nonobstructive azoospermia, but patients should be counseled on the risk of de novo hypogonadism.

Despite this, mTESE success rates remain modest and are subject to the expertise and skill level of the laboratory and andrologist processing the tissue. Multiple hours can be spent trying to find the few viable sperm hidden among a sea of distractors. A recent study by Lee et al examined the power of artificial intelligence to detect human sperm in semen and mTESE samples using bright-field microscopy for nonobstructive azoospermic (NOA) patients.2 They first trained the program to identify sperm from semen samples of fertile patients. After validating the effectiveness of their algorithm, they retrained it to identify sperm in tissue from NOA patients that had been spiked with large amounts of sperm. When testing it on samples containing 3000 to 6000 sperm among other cell types, they achieved 84.0% positive predictive value and 72.7% sensitivity. Finally, without retraining their algorithm, they tested it on samples containing 10 to 200 sperm, replicating the rare sperm phenomenon seen in patients with NOA. Their model was able to detect 2969 sperm cells out of a total 3517 with an 84.4% PPV and 86.1% sensitivity. The clinical applications of artificial intelligence and machine learning in medicine continue to expand and have made their way to male infertility. Although this is not ready for immediate clinical use, it does highlight the need for further work to harness the power of technology to improve workflow of andrologists and in turn increase the success of infertility care for patients.

There has been a rapid rise in the need for male sexual health and reproductive specialists as the population ages and the number of comorbidities rise, although certain disease processes that fall within this specialty may be able to be addressed by a general urologist. In an analysis of the current educational landscape, Asanad et al call attention to the need for a structured educational curriculum in residency for male infertility.3 In a survey of urology residents, 54 of 72 respondents (75%) reported that male infertility comprises less than 10% of their training. Compared with residents who did not learn from infertility-trained faculty, residents who were exposed to infertility-trained faculty were 14.4 times more likely to feel confident performing infertility procedures (P < .001) and were more likely to feel confident performing fertility procedures after residency (P = .001).3 For trainees, their career depends on what they are exposed to. Smaller subdisciplines within urology may be more difficult to teach uniformly, and perhaps there are ways to improve the exposure to these areas for motivated residents (eg, visiting other programs).

Within male sexual health, one disease process that all urologists should be able to diagnose and initially manage is erectile dysfunction (ED). With studies citing the prevalence of ED as high as 52%, the demand for providers to manage ED remains sky high. Current treatment options include phosphodiesterase type 5 inhibitors (PDE5is), intracavernosal injections, vacuum erection devices, and penile prosthesis. A newcomer to the field is shock wave therapy, which uses controlled energy to induce angiogenesis.

The short-term effectiveness of focused shock wave therapy for patients with moderate ED was investigated in a double-blind, randomized, sham-controlled trial.4 In this study of 70 patients with moderate ED, 35 were randomly assigned to low-intensity shock wave therapy (LiST) and the other 35 were randomly assigned to sham therapy. After a 4 week washout from PDE5i, patients underwent LiST or sham twice weekly for 6 weeks. One month after treatment completion, 59% patients in the LiST group experienced an International Index of Erectile Function (IIEF) score improvement of at least 5 points, compared with 1 patient (2.9%) in the sham group (P < .001). This effect remained present at 3 months post treatment. Thus, the short-term data for LiST are compelling and suggest this may be a viable option in the management of vasculogenic ED for men with mild/moderate ED. Further studies are desperately needed to validate these findings, and urologists have an obligation to provide patients with an honest assessment of the data and only recommend treatments where the risks (including the financial burden) are outweighed by the benefits.

In stark contrast to focused therapy, radial shock wave therapy uses low-pressure radial shock waves to treat ED. In order to characterize its effectiveness, a randomized, double-blind, sham-controlled clinical trial enrolled 80 men with mild to moderate ED.5 Patients were treated weekly with either radial wave therapy or sham therapy for 6 weeks, and the primary outcome measured was change in the IIEF score between baseline and after treatment. Study results showed that there was no significant difference in IIEF scores between groups at 6 weeks or 10 weeks after randomization. Study results displayed the lack of evidence to support the use of radial wave therapy.

Despite the evidence of their ineffectiveness in managing ED, shock wave therapy and particularly radial wave therapy have been heavily marketed directly to consumers in the US. A recent article using a secret-shopper method found troubling marketing and practice trends in the US. The authors noted that patients often are not adequately educated on the different types of treatments and may not know if the administrator is a licensed medical professional.6 With the average cost of treatment ranging from $2600 to $3900 per cycle, clinics offering radial wave therapy have an obvious financial incentive to continue marketing despite the lack of evidence of its effectiveness.

Recent advancements in the field of male sexual health and reproduction present a bright future for the field with new diagnostic and therapeutic options on the horizon. However, it is apparent that demand still outpaces supply for mens health specialty care. Urologists must work diligently to fill this void to not only increase access for patients to receive evidence-based care, but also to prevent men from falling to prey to practices looking to take advantage of this unmet demand and a vulnerable patient population.

References

1. Jensen CFS, Ohl DA, Fode M, et al. Microdissection testicular sperm extraction versus multiple needle-pass percutaneous testicular sperm aspiration in men with nonobstructive azoospermia: a randomized clinical trial. Eur Urol. Published online May 19, 2022. doi:10.1016/j.eururo.2022.04.030

2. Lee R, Witherspoon L, Robinson M, et al. Automated rare sperm identification from low-magnification microscopy images of dissociated microsurgical testicular sperm extraction samples using deep learning. Fertil Steril. 2022;118(1):90-99. doi:10.1016/j.fertnstert.2022.03.011

3. Asanad K, Nusbaum D, Fuchs G, Rodman JCS, Samplaski MK. The impact of male infertility faculty on urology residency training. Andrologia. 2022;54(8):e14457. doi:10.1111/and.14457

4. Kalyvianakis D, Mykoniatis I, Pyrgidis N, et al. The effect of low-intensity shock wave therapy on moderate erectile dysfunction: a double-blind, randomized, sham-controlled clinical trial. J Urol. 2022;208(2):388-395. doi:10.1097/JU.0000000000002684

5. Sandoval-Salinas C, Saffon JP, Martnez JM, Corredor HA, Gallego A. Are radial pressure waves effective for the treatment of moderate or mild to moderate erectile dysfunction? A randomized sham therapy controlled clinical trial. J Sex Med. 2022;19(5):738-744. doi:10.1016/j.jsxm.2022.02.010

6. Weinberger JM, Shahinyan GK, Yang SC, et al. Shock wave therapy for erectile dysfunction: marketing and practice trends in major metropolitan areas in the United States. Urol Pract. 2022;9(3):212-219. doi:10.1097/UPJ.0000000000000299

Read more from the original source:
Male sexual health and reproductive medicine: All that glitters is not gold - Urology Times

DUBLIN--(BUSINESS WIRE)--The "Rare Disease Genetic Testing Market Size, Share & Trends Analysis Report by Disease Type (Neurological, CVDs), by Specialty (Molecular, Biochemical), by Technology (NGS, PCR-based), by End Use, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

The global rare disease genetic testing market size is expected to reach USD 2.52 billion by 2030, registering a CAGR of 13.94% over the forecast period, according to this report. Effective regulatory plans to combat rare disease is one of the key drivers of the industry. Furthermore, the presence of a substantial number of registries that provide data and relevant information about related diseases has aided in revenue growth over the past years.

Ongoing conferences to raise awareness about rare and ultra-rare conditions are anticipated to boost the adoption of diagnostic kits and services. For instance, Ergomed and PSR Orphan Experts, with their offices in the U.K., Germany, the Netherlands, Poland, and other countries, participate in various activities that are aimed at raising awareness in this area.

Moreover, the Canadian Organization for Rare Disorders (CORD) offers a strong platform to streamline health policy and a healthcare system that is dedicated to the management of patients with disorders. The agency works with clinicians, researchers, governments, and the diagnostic industry to advance R&D, diagnosis, treatment, and service availability for all rare conditions in the country. As per the National Institutes of Health (NIH), around 30 million Americans have been identified with one of 7,000+ known rare diseases. The number of patients undergoing disease testing is expected to increase in the coming years with growing awareness. The U.S. celebrates Rare Disease Day and promotes developments in this area by raising awareness.

In addition, the presence of the Rare Diseases Clinical Research Network (RDCRN), an NIH-funded research network of 23 active consortia or research groups that includes patients, researchers, and clinicians who are focused on the diagnosis & treatment of disorders is anticipated to positively impact the industry.

Around 50% of the children with learning disabilities and approximately 60% of children with congenital conditions do not receive a definitive diagnosis to identify the cause of their disabilities. Furthermore, the lack of awareness among patients and families about diagnosis and genetic testing has further impeded the industry's growth.

North America dominated the industry in 2021 due to the high incidence of rare diseases, a large number of registries, the presence of substantial numbers of R&D facilities in this area, and extensive investments in diagnosis. Asia Pacific is expected to register the fastest CAGR during the forecast years owing to the presence of a substantial number of organizations that are focusing on disease management.

Rare Disease Genetic Testing Market Report Highlights

Market Dynamics

Market Drivers

Market Restraints

Market Opportunities

Market Challenges

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Market Variables, Trends, & Scope

Chapter 4 Industry Outlook

Chapter 5 Disease Type Business Analysis

Chapter 6 Technology Business Analysis

Chapter 7 Speciality Business Analysis

Chapter 8 End-Use Business Analysis

Chapter 9 Regional Business Analysis

Chapter 10 Company Profiles

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/515scb

Read the original here:
Global Rare Disease Genetic Testing Market Report 2022: Ongoing Conferences to Raise Awareness About Rare and Ultra-Rare Conditions to Boost Growth -...

SOUTH SAN FRANCISCO, Calif. & ST. LOUIS--(BUSINESS WIRE)--Genome Medical, the leading telehealth provider of genetic services and genomics-based care, and Pierian, the global leader in advanced clinical genomics technology and services, announced a collaboration designed to streamline and optimize onsite genomics programs for health care organizations and provider groups. The companies services, when combined with genomic testing capabilities, create an end-to-end patient and clinician experience that elevates standards of care and patient outcomes.

Genome Medical and Pierian are working together to efficiently identify patients who may benefit from genomic testing and an enhanced clinical genomics workflow. The combined solution for clinicians facilitates the ordering of appropriate testing which is then processed in onsite laboratories supported by Pierian.

First, through its RISE Patient Engagement Modules, Genome Medical helps clinicians Reach, Inform, Support and Educate patients. RISE includes a Hereditary Cancer Risk Assessment Module that collects and analyzes family and personal health history to determine if a patient meets genetic testing criteria for hereditary cancer. When criteria is met and testing is ordered, laboratory customers utilize Pierians advanced technology platform to ingest, analyze, interpret and report on genomic insights for more precise care.

For physician-owned or -managed service organizations, Pierian and Genome Medical deliver a streamlined path to in-house, high-quality precision medicine programs that provide recommended and appropriate care to all patients who meet national standards for genomic testing. This can also include virtual post-test genetic counseling from Genome Medicals nationwide team to help explain the test findings and advise on recommended follow-on care, if needed.

We are excited to partner with a like minded innovator, Genome Medical, to combine our leading edge platforms and expertise to enable the clinicians we are privileged to serve, said Mark McDonough, CEO of Pierian. At Pierian, we are passionately committed to catalyzing precision medicine at scale through our tools, our team, our customers, and our partners like Genome Medical. We are united in our belief that all patients deserve access to high quality, affordable, genetic testing.

Genome Medical has pioneered a virtual model of tech-enabled care delivery and assembled an unmatched team of genetic specialists, enabling rapid, efficient access to genetic counseling and related services. The company offers flexible genetic services programs to approximately 100 partners, including health systems, diagnostic testing labs, insurers, and other partners. In addition, its services are a covered, in-network benefit for more than 160 million people in the U.S.

Genome Medical is pleased to be able to partner with Pierian to bring our patient screening and clinical genetic services to provider groups who are looking to improve and expand their genomic testing programs, said Jill Davies, CEO of Genome Medical. This collaboration represents two industry leaders delivering the services and tools that will make in-house genomic testing programs accessible to a wider array of providers and patients.

Pierian partners with academic centers, health systems, physician-owned laboratories and reference laboratories worldwide to establish high-quality clinical genomics programs and a global sharing network. With advanced interpretation technology connected to the most comprehensive knowledge base, Pierians unique, adaptive learning algorithms make intelligent associations between comprehensive datasets and individual patient results. Post analysis and interpretation, clinical reports are easy to generate, which empowers clinicians with genomic insights to fulfill the promise of precision care.

About Genome Medical

Genome Medical, the leading genomic care delivery company, is personalizing health care for all through on-demand access to genetic insights and genomic medicine. We operate as an independent virtual medical practice, powered by a digital health technology platform. By partnering with health systems, providers, health plans, employers, labs and biopharmaceutical companies, we expand the reach and impact of precision medicine. We provide clinical assessments and tools, test recommendations and ordering, and personalized care plans to deliver optimal patient care and improve health outcomes. The company, which is headquartered in South San Francisco, has been honored as The Best Digital Health Company to Work For by Rock Health, Fenwick & West and Goldman Sachs in their Top 50 in Digital Health awards. To learn more, visit genomemedical.com and follow @GenomeMed.

About Pierian

Pierian is a partner in precision medicine, enabling clinicians and medical facilities to advance clinical genomics programs and modernize patient care. We believe in the potential of genomics to transform human health and are working to ensure that communities anywhere can experience the benefits. We curate the worlds genetic knowledge, and our advanced interpretation technology combines this knowledgebase with adaptive learning algorithms that connect diverse sources of information through machine learning. When applied in clinical settings our platform is paired with our enabling services which support workflow design, implementation, validation, interpretation, and reimbursement. For more information, visit http://www.pieriandx.com.

Originally posted here:
Genome Medical and Pierian Announce Collaboration to Optimize Genomic Testing Programs - Business Wire

DNA testing has become increasingly popular over the years, with one of the most prominent companies being DNAfit. DNA testing claims to assess your genetic makeup, ultimately helping users gain insights into their health and fitness that they wouldnt otherwise have. The company can then use this information to tailor a unique workout and diet plan specifically designed for your body.

DNAfit claims to provide some of the most comprehensive DNA testing available. The company also states that it can provide unrivaled insight into users diet, nutrition, fitness, and well-being. However, some of the health claims they make are unsupported by evidence, and theres little scientific evidence for DNA-based personalization. For these reasons, we dont recommend purchasing or using DNAfit kits.

Read on to discover what you need to know about this company and alternatives to consider.

DNAfit is a direct-to-consumer genetic testing company that provides DNA-based insights into diet, fitness, and wellness. The London-based company was founded in 2013 by Avi Lasarow to provide people with a simple way to understand how their genes affect their health and fitness.

The company offers three main products: Diet Fit, Heath Fit, and Circle Premium, with the latter being its most comprehensive option. Each kit provides everything you need to collect a DNA sample from home and send it to their state-of-the-art laboratory for analysis.

Once the results are ready, youll receive a personalized report with actionable insights and recommendations based on your unique genetic makeup.

The primary aim of DNAfit is to provide you with information you can use to improve your health and fitness.

The company offers three different tests, each with a different focus:

We evaluated DNAfit by looking at the companys medical claims and business standards.

Although the company doesnt make any disease claims, some of its health claims are unsupported by solid scientific evidence. For example, personalizing diet and fitness plans according to your genes doesnt correlate with the available evidence.

Likewise, claims that DNA testing results can help you effectively manage stress and sleep are largely unfounded.

In regards to business standards, DNAfit fared well. They have no Food and Drug Administration (FDA) warnings or third-party certifications. Additionally, the company has good privacy standards with SSL encryption and a valid security certificate.

DNAfit is owned by a parent company called Prenetics, which currently doesnt have a Better Business Bureau page. They do, however, have a 3.9-star rating from more than 4,500 reviewers on Trustpilot. Meanwhile, DNAfit has a 3.8-star rating on Trustpilot.

Diet Fit is the most basic of DNAfits offerings. It provides insights into your unique nutrigenetic profile, which is designed to help you understand how your body responds to various types of food and any sensitivities and intolerances you may have. According to the company, youll find out which foods you should eat more or less of to lose weight, maintain weight, or gain muscle with personalized dietary recommendations.

Youll also receive information on building your perfect meal according to how you respond to carbohydrates and fats. You can program the MealPlanner (a personalized meal planning service) with your aim, likes, and dislikes, and it generates a genetically guided recipe plan complete with a shopping list builder.

Health Fit further builds on the diet and nutrient insights from Diet Fit. Youll receive the same insights and have access to the personalized MealPlanner.

Where Health Fit differs is with its fitness response genetic markers. These markers include:

These insights allow you to discover how to optimize your workouts and guide your training choices.

Youll receive information on your stress and sleep profile to help you improve your mental and physical well-being.

Circle Premium is DNAfits most comprehensive offering. In addition to the information provided in Diet Fit and Health Fit, the Circle Premium report is said to assess your genetic risk of certain diseases like dementia, type II diabetes, irritable bowel syndrome, and others.

The aim is to help you better understand your health and take preventive measures like lifestyle changes, check-ups, or more frequent cancer screenings.

It includes over 350 reports covering:

For those thinking of starting a family, the reports provide information on any inherited conditions that could be passed down to future generations.

When you receive your DNAfit report, its important to keep in mind that its only one part of the picture. The results should be used as a guide and not as a certainty.

For example, if your report says you have a higher risk of developing type II diabetes, it doesnt mean youll definitely have the condition in the future. Likewise, a lower risk doesnt necessarily mean symptoms of the condition wont occur.

Remember that your DNA is just one factor in the development of disease. Other important considerations are your lifestyle choices, environment, and more.

The Diet Fit report is easy to understand and isnt too dense in information. It details how your genetics may affect the way you metabolize carbs and fats. It also outlines if you have the required needs for certain vitamins or nutrients.

There are sections for:

The meal planner feature allows you to input your food preferences and generates a genetically tailored meal plan.

The Health Fit report is similar to the Diet Fit report in terms of content and layout. However, it builds on the information with details on how your genes affect fitness levels and provides insights on optimizing your workouts.

It includes:

Theres also information on your stress and sleep profile. The results outline how you cope with stress and your tolerance levels. Youll also find out if youre a warrior or a strategist, which identifies how you process information and perform tasks while under stress.

The Circle Premium report is DNAfits most comprehensive offering. In addition to the information provided in Diet Fit and Health Fit, the Circle Premium report provides the following information:

Youll also discover your ancestry and information on various traits. These include success, behavioral, physical, personality, and gender so you can better understand yourself and your background.

DNAfit claims that they take users privacy very seriously. It was the first company of its kind to become certified by ISO 27001, a globally recognized framework for best practices on information storage and security.

Rather than by name, DNAfit stores your data by ID number and claims that they destroy your samples after use. Your data wont be shared with people outside the company, and DNAfit does not sell your information to third parties.

Here are some other brands that provide DNA testing services. These recommended alternatives have passed Healthlines medical and business standards.

Everlywell provides a convenient way of checking different health issues from allergies to STIs and food sensitivities. However, theres a lack of evidence to support the methods they use for testing food sensitivities. Experts feel that these tests can provide inaccurate and misleading information, so its important to take these results with discretion.

Overall, Everlywell has a solid reputation besides the criticism about their controversial food sensitivity testing. They also use Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories, so youre sure of quality service and results.

Everlywell sells a wide range of at-home testing kits that cover:

Like Everlywell, myLAB Box offers a convenient way to test for STIs and other health conditions from the comfort of your home. In addition, they offer free shipping and results in as little as 2 to 5 days.

They offer sensitivity testing for 96 different foods, and they test for IgA, IgG, and IgG4. This might provide a better picture than relying on IgG alone. But, bear in mind that the test doesnt test for food allergies, as this requires IgE antibody testing.

Other home tests sold by myLAB Box include:

FoodMarble uses a type of breathalyzer that claims to help you figure out which foods cause digestive issues. The device is small and portable, so you that can take it with you on the go.

To use it, you simply breathe into the device after eating, and it tells you if the food is digesting properly. The device measures hydrogen levels in your breath, and together with the app, it provides accurate information.

FoodMarble sells two breathalyzers:

If you still decide that youd like to try out DNAfits at-home DNA test kits, there are a few things to keep in mind before purchasing.

You should first talk to your doctor, who can more accurately assess your medical, health, and family history. They might be able to provide personalized suggestions based on your diet and fitness patterns, especially if youre looking to lose weight. They may also be able to provide some insights by talking through factors like stress, sleep, and your general well-being.

Your doctor may also be able to suggest lab or food sensitivity tests that can provide information regarding food intolerances and your risk of certain diseases like diabetes.

The brand passed our business vetting standards, meaning its a reputable company without any FDA or Federal Trade Commission (FTC) warnings against them. There also havent been any lawsuits filed.

DNAfit does not yet have a Better Business Bureau page, and its products do not appear on Amazon.

However, it has a Trustpilot page that scores DNAfit 3.9 out of 5 stars with more than 2,500 reviews. Although the reviews are good overall, some customers were unimpressed. They claim that the information provided is very basic and vague.

Users also reported problems with accessing the app and poor customer service.

In short, probably not. No scientific evidence supports claims that these tests can help you lose weight or improve your fitness.

A 2018 study found that DNA testing couldnt help guide people to a specific weight loss regimen that was more likely to be successful. Although many companies claim these effects, it seems there is no difference in weight loss between people following diets that allegedly match their genotype compared to those on standard diets.

The services offered by DNAfit are not inexpensive, starting at around $150 for Diet Fit. However, there is little scientific evidence underpinning their value, so its unlikely that DNAfit is worth the money.

That said, many of the reviews on Trustpilot are positive, with some people stating they would happily recommend DNAfit. So, it comes down to personal choice and budget as to whether DNAfit is worth it to you.

DNAfit states that their at-home DNA tests are accurate, but its tricky to find specific figures. However, they claim to regularly spot-check their labs to ensure they test samples correctly and provide results that are 100% accurate.

Currently, the FDA has only approved 23andMe for some of their at-home DNA tests. Overall, the industry is not regulated and has no independent analysis to verify the sellers claims, so you should still use caution when purchasing a test.

However, generally, DNA testing is a safe procedure. Most kits require a cheek swab or saliva sample, so there are essentially no associated risks. But, when samples are self-collected at home, theres an increased risk of contamination and inaccuracies.

DNAfit is a direct-to-consumer DNA testing company that offers several different tests, including Diet Fit, Health Fit, and Circle Premium.

The company has a good reputation, with few complaints from customers. However, the scientific evidence underpinning the value of their tests is lacking, and there are health claims unsupported by evidence.

Overall, its unclear whether DNAfit is worth the money, and we dont recommend purchasing or using the service for these reasons.

Zia Sherrell is a health copywriter and digital health journalist with over a decade of experience covering diverse topics from public health to medical cannabis, nutrition, and biomedical science. Her mission is to empower and educate people by bringing health matters to life with engaging, evidence-based writing.

View original post here:
DNAfit Review: What It Can and Can't Tell You - Healthline

Jen Culton, a 48-year-old mom of four from Omaha, Nebraska, never thought much about genetic mutations. "I had read in magazines that Angelina Jolie had a preventative double mastectomy, and I thought, 'That's really aggressive for someone who doesn't even know if she's going to get breast cancer,'" Culton said. A family diagnosis changed her perspective on her own health and that of her daughters.

In July 2013, Culton's older sister who was 38 years old at the time learned she had breast cancer. A genetic test showed she had a gene mutation called BRCA1 predisposing her to cancer, so her oncologist suggested all of her siblings get tested. That's when Jen learned she had the same mutation.

According to the National Cancer Institute, people who inherit BRCA gene mutations have an increased risk of multiple cancers, particularly breast and ovarian. They also tend to develop these cancers earlier than people who don't carry these mutations.

People who learn they have these genetic mutations can take steps to screen for early signs of cancer, or to prevent the cancers from developing altogether.

Culton ultimately had all of her reproductive organs and her breasts surgically removed, drastically lowering her risk of developing ovarian or breast cancer. Now, she's tasked with potentially guiding her daughters down a similar path.

Culton's two older daughters have already undergone genetic testing. So far, only Sammi Jen's 19-year-old has tested positive for the BRCA1 mutation. "I cried all day, because I felt guilty that I passed this on to her, but Sammi took the news extremely well," Culton said.

Sammi's already entertaining the idea of having the same surgeries her mom did, but it'll probably be a few years before she takes any medical-preventative action.

The National Comprehensive Cancer Network, an organization that develops preventative guidelines for people with a high risk of genetic conditions, currently advises medical providers to begin screening people with a BRCA1 or 2 mutation in their 20s regardless of when they learn about the mutation.

For people with a BRCA1 mutation, guidelines recommend routine breast imaging to detect early signs of breast cancer beginning at age 25. Screening may start sooner for people with a family member who had cancer at a younger age.

"It's very rare for a BRCA1 carrier to have breast cancer younger than age 25," Nicolette Chun, a genetics counselor at the Stanford Cancer Institute, said. "If there is a family history of breast cancer under age 30; we start MRI screening as young as 20."

In place of breast screening, people with BRCA mutations can have mastectomies, or surgical removal of the breasts, at any point. Medical experts usually recommend oophorectomies, or the removal of one or both ovaries, around age 40 or sooner for those who either don't want kids or are done having them.

Culton's 10-year-old daughter, Daisy, has asked about the mutation, but Culton doesn't plan to screen her until she's at least 18. "My husband and I don't want to cause anxiety or put pressure on her, especially because you can't do anything if you find out you have the mutation that young," Culton said.

Experts agree that finding out about a mutation as a child or teen may do more harm than good.

Most major health organizations, including the National Society of Genetic Counselors, advise against testing minors for adult-onset conditions: There's no medical action to take, and learning about a mutation can cause unneeded fear and anxiety for years to come.

"When deciding about genetic testing, we have to consider the effects it's going to have on a person's healthcare, but we also have to think about the person's mental health," Skyler Jesz, a board-certified physician assistant who has worked with Culton and other patients to decide when to perform genetic testing, said. "It's difficult for an adult to have a conversation about an increased risk, let alone a 10-year-old."

While learning about a genetic mutation gave Culton a sense of control over her own health and she feels a sense of responsibility over her daughters' well-being protecting her daughters includes prioritizing their mental health. "I want Daisy to have a childhood," she said. "We can deal with this when she's older."

Go here to read the rest:
One of my daughters and I have the BRCA1 gene mutation - Insider

Direct-to-consumer home genetic kits allowed startups like 23andMe to offer health and ancestry insights at an affordable cost. Now, similar tech is coming to pets.

Itll help vets, breeders and pet parents to verify parentage and breed, diagnose diseases and plan for future health risks.

Everything we have seen happening in humans, in terms of predictive and personalised medicine and genetics-based diagnostics, has migrated into the pet space, says Sergey Jakimov, founding partner of LongeVC, a European VC fund that focuses on early-stage biotech and longevity. This is super exciting because pets, as living beings, have equalised themselves in importance in terms of how much money and attention is spent on their longevity, and in disease diagnostics and prevention.

Its not the first time human health innovation has come to the animal world US-based Signal Pet, for example, provides artificial intelligence-based radiology but animal genetics could be big business.

Animal genetics market revenue is predicted to exceed $6.4bn by 2027, up from $99m in 2020. Sifted dug into the sector and found the startups to watch and the VCs watching them.

Feragen, an Austria-based pet genetics startup, sees the vet sector as a growth engine for its business. It wants to move from diagnostics, where such tools are common, into disease prevention.

Puppies are more like family members

We want to push the prevention angle. What can we learn from genetics to create a life plan for a dog? says Anja Geretschlger, founder and CEO. Pet parents are becoming more interested in understanding the risk of diseases that might come when the pet is five or six, so they are more prepared when the symptoms show up.

Michael Geretschlger, Anjas husband and collaborator, says preventive health is getting more [attention] as puppies are more like family members. Anja Geretschlger adds that genetic insights are valuable for breeders in the era of designer dogs.

This is because cross-breeding can lead to health complications, such as labradoodles developing skin problems due to different fur structures between labradors and poodles.

Another European player is Germany-based Generatio, which provides genetic testing for animal owners, vets and breeders.

Theres also UK-based AffinityDNA, acquired in May by Australian diagnostics company Genetic Technologies, which provides animal testing for allergies and intolerances, paternity testing and direct-to-consumer (DTC) genetic tests from companies like Embark, Wisdom Panel and BasePaws.

Genetic Technologies portfolio includes General Genetics Corporation and associated brand EasyDNA, which offers UK pet owners breed composition tests, disease susceptibility tests for dogs, and feline and equine offerings.

European VCs are also interested in startups across the pond. Garri Zmudze, a Latvian biotech angel investor and founder of Switzerland-based LongeVC, investedin Basepaws, the American cat genetics company recently acquired by Zoetis, an animal medicines and vaccinations company.

Basepaws plans to expand into the veterinary portfolio of genetic, oral and microbiome screening tools for disease risk, screening 64 feline health markers and over 210 canine health markers.

For some, the pet genetics space is not just a play on the pet market but could inform human health and longevity science. Some diseases are rare in humans but are common in certain breeds of pets, who are useful for studies into genetic disease origins.

There is a tight connection between humans and animals and we can learn from both, says Anja Geretschlger.

Zmudzes investment in Basepaws, for instance, was not a pet consumer market bet at all. Instead it was aligned with his interest in human longevity, given the genetic overlaps between animals and humans in diseases like cancer and some neurodegenerative conditions.

There is a tight connection between humans and animals and we can learn from both

These overlaps are the reason we have animal models in clinical trials, because the metabolic processes are translatable, says Jakimov. There are tonnes of matches.

Matt Kaeberlein, professor of laboratory medicine and pathology at the University of Washington School of Medicine and head of the dog ageing project, a world-leading biological study of ageing in dogs, sits on the LongeVC advisory board, alongside executives from European pharmaceutical giants Roche and Novartis. And Zmudze was also an investor in Insilico Medicine, an AI drug discovery unicorn.

As home to many of the worlds top pharmaceutical companies, Europe could be a major player in longevity research. Switzerland is developing a Longevity Valley initiative, Bristol Myers Squibb and Merck are major investors in cancer immunotherapies and the pharma industry is investing in early stage longevity companies like senescent cells companies, through initiatives like Mercks early stage venture arm.

Pharmaceutical companies live in the future, they live in 10 to 20 year cycles, says Jakimov. They are super focused on the longevity sector.

This article first appeared in our monthly Unleashed pet tech newsletter, a collaboration with Purina Accelerator Lab. All content is editorially independent.Sign upto our newsletter here to keep up to date with the latest goings on in the European pet tech industry.

More here:
Purrsonalised health: The startups and VCs betting on pet genetics - Sifted

The need for understandable and transparent pricing for medical services in the U.S. has increased in urgency with the continuing rise of out-of-pocket healthcare costs.

Americans are delaying healthcare because they are unsure of the cost or they cannot afford it. A recent Willis Tower Watson (WTW) survey of 9,600 U.S. workers showed that 4 in 10 people deferred healthcare in the past year, with 28% delaying or canceling a medical procedure and 17% not filling a prescription.

Recent federal mandates are inching price transparency forward with the goal of improving care while reducing waste and reigning in costs. With lab values as the basis for 70 percent of medical decisions, lab testing transparency for price and appropriate use is essential to lowering costs for patients.

But price transparency goes beyond reducing costs. It will realign how labs, providers, and payers work together to order, approve, and pay for the right care that moves us closer to the Triple Aim of improving the patient experience, improving the health of populations, and reducing costs.

You cant flip a transparency switch

Unfortunately, the lab testing industry cant flip a switch and make transparency universal.

With healthcare affordability as a big concern, Americans are becoming more involved in managing their care, and that includes switching health insurance plans to secure the best benefits and reduce out-of-pocket costs. To help support these consumer decisions, recent federal regulations were enacted.

Even with the government stepping in to improve access to pricing data and reduce unexpected costs, we are still far from having universal lab testing transparency. Achieving full transparency will require: 1) coordinated education, 2) simpler data access, and 3) the strategic implementation of payment integrity programs to eliminate unnecessary lab tests while identifying underutilized tests that improve patient care and outcomes.

Location, location, location

Education about the impact of lab testing location on cost has to move upstream in the care process. Today, that often happens after the lab test has occurred. Patients and their physicians need to understand and discuss which lab testing locations bring the most value and inform the best care.

The lab test location can result in increased costs, over-testing, and unnecessary tests.

Hospital-owned labs are typically paid more than independent labs. Lab tests performed at hospital-owned labs are generally 2.5 to 4.5 times the cost of an independent lab. Avalons analysis of paid claims demonstrates that hospital outpatient labs are paid on average 300%-400% of Medicares independent diagnostic fee schedule. Hospitals frequently argue they need to charge more to support their specialty test innovation and development. That doesnt hold true for routine testing, though. For example, some hospitals will be reimbursed $100 for a routine test, while an independent or non-hospital lab will be reimbursed on average $20 for the same test, performed on the same machine.

Physician office lab testing is more costly and more frequent. When physician offices have their own lab equipment, our analysis of paid claims demonstrates that physician offices are reimbursed on average 120% to 130% of Medicares independent diagnostic fee schedule for those tests. In addition, the frequency of lab testing increases when the laboratory testing is performed in the physicians office. When the elapsed time between tests is less than the time it takes for the body to produce new chemicals in the body (measured by the half-life of the chemical) this is not a clinically useful frequency of testing.

Our analysis of paid claims demonstrates independent labs conduct the most clinically useless test units. The laboratory industry develops the test order menus from which physicians order labs. While developing panels, which represent useful tests commonly ordered together, the labs will add additional tests that are not useful to the physicians diagnostic evaluation. This is known as panel stuffing in the industry. Panel stuffing is a wasteful practice that adds unnecessary tests (those that dont comply with a health insurance plans published policies) within routine lab panels and increases test costs for patients.

Consider that several labs add an experimental subcomponent analysis of Vitamin D to the Vitamin D panel menu. Also, consider that many labs, on the menu for evaluation of thyroid, include seven unique tests when two are important to the most common clinical scenarios. This raises the cost of routine thyroid testing from around $30 to about $137.

Lab tests that lack clinical indications can lead to unneeded sample collection from patients as well as a higher risk of false-positive results and unnecessary costs. We identified that on average there is approximately $2 per member/per month worth of obvious waste in processed claims. This represents the total amount allowed for the testing. Patients, on average, pay 1/3 of the cost at the point of service and payers pay the other 2/3 of that cost. Another way to look at this same data is that for every 1 million members with health benefits, approximately $24MM dollars of useless testing is reimbursed per year, with patients paying $8MM of that out of pocket.

Promoting lab testing at the right locationfor both cost and caremay be harder than it sounds. Physicians who are part of health systems may be pressured and/or incentivized to send patients to the affiliated hospital labs. Plus, payers are often hesitant to educate their members about lower-cost lab testing options because of various provisions in their contracts with hospitals.

Sharing the facts about lab testing locations will require a national education campaignmuch like the campaign conducted for the $0 co-pay generic drugsto motivate patients to insist on having lab testing performed at lower-cost locations and to only pay for tests that benefit patient care.

Right test, right time, right care

Patients, providers, and payers all want the right care. Appropriate lab testing is a critical driver behind this. The demand for lab testing is growing as more providers recognize the importance lab results play in confirming the diagnosis, monitoring patients treatment responses, and monitoring diseases significant to public health (i.e., Covid-19). The high prevalence of chronic and acute diseases, an aging population, and advancements in genetic testing are also fueling this growth. There is an expected 10% compounded annual growth rate through 2029.

Receiving the right care should be as simple as having the right lab test at the right time (in the right location). However, the current healthcare ecosystem includes trends that undermine the journey to this valuable goal. When looking closely at the 13+ billion lab tests performed annually across the U.S., 30% of lab tests are unnecessary, 30% of patients dont receive the tests they need, and 1 in 3 genetic tests are ordered in error.

When you consider that lab testing is the gateway for diagnosis and treatment of many conditions, it transforms each test from being a passive event to a critical data point for proactive value-based care success. With this backdrop, a payment integrity program that includes lab benefit management can serve as a strategic lever to curb these negative testing trends and advance the Triple Aim.

With sound science at the core, payment integrity programs provide input from policies developed by independent clinical boards on what types of tests are not evidence-based and emphasize the appropriate units for routine and genetic testing. This process flags non-adherent tests (from both panel stuffing and inappropriate genetic test orders) and underutilized tests that can inform patient care, especially in cancer care.The ultimate impact is for patients to receive the right tests at the right time to better inform diagnoses and care plans, reduce waste in time and treatments that are not helping patients, and achieve cost alignment that drives the right outcomes.

As the U.S. healthcare industry continues to advance value-based care and population health, lab testing price transparency and payment integrity programs should be a priority.

Photo: champc, Getty Images

Excerpt from:
Lab testing transparency will improve patient care and lower costs - MedCity News

A new tool that uses artificial intelligence (AI) to analyze healthcare records may aid in the early diagnosis of fragile X syndrome, a new study reports.

By incorporating a combination of co-occurring conditions, an AI-assisted pre-screening tool was developed and validated to identify potential cases at least 5 years earlier than the time of clinical diagnosis, the researchers wrote.

The scientists said their AI tool was used successfully to analyze a healthcare database in the U.S. state of Wisconsin. Moving forward, this artificial intelligence-based program could be used across other healthcare databases to better and potentially much sooner identify individuals who may be affected by fragile X.

Our AI-assisted pre-screening approach can facilitate and accelerate the clinical diagnosis of [fragile X syndrome] and decrease the duration of the diagnostic odyssey and degree of stress experienced by patients and their families, the team wrote.

One concern in the move forward is that the AI tool thus far was only used in healthcare systems that were predominately comprised of white patients. More testing and validation is needed in other racial and ethnic patient populations, the researchers said.

The study, Advancing artificial intelligence-assisted pre-screening for fragile X syndrome, was published inBMC Medical Informatics and Decision Making.

Fragile X syndrome can manifest very differently from person to person, which makes diagnosing the genetic disorder a challenge. Studies have shown a marked gap between the estimated prevalence of fragile X and the actual number of people diagnosed suggesting that as many as 70% of people affected by fragile X syndrome have not been properly diagnosed.

To bridge that gap, a team led by scientists at the University of Wisconsin-Madison created an artificial intelligence tool aimed at better diagnosing fragile X syndrome. This tool is applied to data that is routinely collected in electronic healthcare records (EHRs).

Their aim was to identify data in such EHRs that could predict the diagnosis of fragile X, even before the disorder itself is formally diagnosed.

The pre-screening model is not intended to be a replacement for genetic testing, but it can serve as a tool to automatically alert physicians about the presence of multiple [fragile X syndrome]-related phenotypes in the patients medical records, the scientists wrote.

By prompting the physician to further evaluate such individuals and refer them for genetic testing and counseling, our approach could accelerate the diagnostic process and be instrumental in identifying un-diagnosed individuals in the population and addressing their health conditions, the team wrote.

To create the tool, the team used EHR data collected from 1979 to 2018 served by the Marshfield Clinic Health System in Wisconsin.

From the data, the team identified 55 people who had been diagnosed with fragile X syndrome at an age of 10 or older. The scientists also used data from 5,500 people without a fragile X diagnosis, who were similar to the patients in terms of age and sex.

For all of these patients, the researchers extracted data from five years before the formal diagnosis of fragile X syndrome, or the equivalent ages for controls.

All data used in this study are directly collected in a medical setting and are in fact real world data from actual patients, providing further proof of [the AI tools] potential utility in real world clinical applications, the team noted.

With these data in hand, the researchers then trained their artificial intelligence algorithm using a mathematical strategy called random forest. Conceptually, the AI tool uses a set of mathematical rules to look for patterns in the diagnostic codes that could differentiate between people with or without fragile X syndrome.

To test the utility of the trained algorithm, the scientists tested it on data collected from UW Health, a separate healthcare system in Wisconsin.

Our next step, reported here for the first time, was to evaluate the performance of this model in a new unseen dataset, i.e., an external validation study, they wrote.

In this dataset, the team identified data for 52 fragile X cases and 5,200 people without the disorder, matched for sex and age.

To test the tools accuracy, the researchers calculated a statistical measurement called the area under the receiver operating characteristic curve, or AUROC. This is basically a measurement of how well a test can tell the difference between two groups i.e., fragile X or not. AUROC values can range from 0.5 to 1, with higher values suggesting better ability to discriminate.

In the original Marshfield dataset, the AUROC for the AI tool was 0.798. In the UW Health analysis, it was 0.795.

The AUROCs of the predictive models created and evaluated using the Marshfield cases and the UW Health cases were almost identical (0.798 vs. 0.795), representing the high level of reproducibility of results in different health care systems, the scientists wrote.

Our AI-assisted pre-screening tool could significantly improve the diagnostic process and could provide substantial benefits for patients, families and the health care system, they concluded.

A noted limitation of this analysis was that nearly 90% of patients in both healthcare systems were white. The researchers highlighted a need to further validate this model in other populations, especially those of non-European ancestry.

Additional studies on larger populations will provide more precise information on the performance of the model, they wrote.

Read the rest here:
Artificial Intelligence Tool May Help in Early Diagnosis of... - Fragile X News Today